tadalafil has been researched along with sildenafil citrate in 432 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (sildenafil citrate) | Trials (sildenafil citrate) | Recent Studies (post-2010) (sildenafil citrate) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 5,862 | 956 | 2,319 |
| Protein | Taxonomy | tadalafil (IC50) | sildenafil citrate (IC50) |
|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 171 (39.58) | 29.6817 |
| 2010's | 199 (46.06) | 24.3611 |
| 2020's | 62 (14.35) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, J; Chen, Y; Geng, H; Guo, L; Huang, Y; Huang, YY; Li, Z; Luo, HB; Wu, D; Zhang, C; Zhang, T | 1 |
| Brock, G | 1 |
| Jackson, G | 1 |
| Cartledge, J; Eardley, I | 1 |
| Rotella, DP | 1 |
| Gleiter, CH; Gresser, U | 1 |
| Satyanarayana, R; Vickers, MA | 1 |
| Cestari, A; Deho', F; Guazzoni, G; Montorsi, F; Rigatti, P; Salonia, A; Stief, C | 1 |
| Wyllie, MG | 1 |
| Jünemann, KP | 1 |
| McKenna, KE; Rosen, RC | 1 |
| Mason, RG | 1 |
| Kuthe, A | 1 |
| Cho, JM; Eum, SJ; Heo, YS; Hwang, KY; Hyun, YL; Jeon, YH; Kim, E; Kim, JH; Lee, JI; Lee, JO; Lee, TG; Moon, J; Park, SY; Ro, S; Sung, BJ; Yoon, JM | 1 |
| Kostis, JB; Rosen, RC | 1 |
| Ahuja, S; Denne, J; Govier, F; Kaufman, J; Kovalenko, P; Potempa, AJ | 1 |
| Costigan, T; Murphy, A; Ströberg, P | 1 |
| Sohn, W | 1 |
| Naughton, K | 1 |
| Beasley, CM; Costigan, T; Denne, J; Emmick, JT; Lockhart, D; Murphy, A; Rajfer, J; Segal, S; von Keitz, A | 1 |
| Dinsmore, W | 1 |
| Romics, I | 1 |
| Kirkpatrick, P; Neumeyer, K | 1 |
| Briganti, A; Gallina, A; Montorsi, F; Rigatti, P; Salonia, A; Suardi, N | 1 |
| Burnett, AL | 1 |
| Beasley, A; Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Sekhar, KR; Zoraghi, R | 1 |
| Bischoff, E | 1 |
| Larsen, A | 1 |
| Del Popolo, G; Li Marzi, V; Lombardi, G; Mondaini, N | 1 |
| Brandetti, F; Carosa, E; Di Stasi, SM; Jannini, EA; Lenzi, A; Lombardo, F; Martini, P | 1 |
| Bakker, F; Blok-Tip, L; De Kaste, D; Hamzink, M; Hartog, KD; Ten Hove, J; Vredenbregt, M; Zomer, B | 1 |
| Ghofrani, HA; Grimminger, F; Haredza, P; Karadaş, B; Olschewski, H; Reichenberger, F; Schermuly, RT; Seeger, W; Voswinckel, R; Weissmann, N | 1 |
| Beasley, CM; Crumb, WJ; Dustan Sarazan, R; Emmick, JT; Ferguson, KM; Sausen, PJ; Strnat, CA | 1 |
| Anderson, PC; Arya, M; Gommersall, L; Hayne, D; Patel, HR | 1 |
| Berzas Nevado, JJ; Castañeda Peñalvo, G; Mora Diez, N; Rodríguez Flores, J | 1 |
| Kloner, RA | 2 |
| Keil, TU | 1 |
| McCullough, A | 1 |
| Wooten, JM | 1 |
| Aufiero, K; Belardi, D; Champion, HC; Dostmann, WR; Isoda, T; Kass, DA; Mergia, E; Mongillo, M; Montrose, DC; Moslehi, J; Smith, CJ; Takimoto, E; Zaccolo, M | 1 |
| Goldstein, I; Lewis, JH; Rosen, R | 1 |
| Perimenis, P | 1 |
| Doggrell, SA | 1 |
| Campbell, HE | 1 |
| Chen, B; Han, H; Wan, Z; Xiao, S; Yang, D; Yao, S; Zhang, F; Zhu, X | 1 |
| Whitehill, D | 1 |
| Egan, RA; Fraunfelder, FW | 1 |
| Baumhaekel, M; Boehm, M; Scheffler, P | 1 |
| Beasley, A; Blount, MA; Corbin, JD; Francis, SH; Sekhar, KR; Thomas, MK; Weeks, JL; Zoraghi, R | 1 |
| Takahashi, Y | 1 |
| Adomat, H; Eberding, A; Fleshner, N; Guns, E; Harvey, M; Hersey, K; Wood, C | 1 |
| Hatzichristou, DG; Hatzimouratidis, K | 1 |
| Gupta, M; Kovar, A; Meibohm, B | 1 |
| Hackett, GI | 1 |
| Priviero, FB; Teixeira, CE; Webb, RC | 1 |
| Huang, YR; Jin, W | 1 |
| Agrawal, A; Castell, DO; Hila, A; Tutuian, R | 1 |
| Barbieri, L; Briganti, A; Deho', F; Montorsi, F; Rigatti, P; Salonia, A; Zanni, G | 1 |
| Beardsworth, A; Eardley, I; Kell, P; Mirone, V; Montorsi, F; Ralph, D; Warner, MR; Zhao, Y | 1 |
| Brown, M; Lambert, SM; Masson, P; Shabsigh, R | 1 |
| Hayreh, SS | 1 |
| Brown, JW; Fiore, AC; Meldrum, DR; Sheridan, BC; Tsai, BM; Turrentine, MW; Wang, M | 1 |
| Seftel, AD | 1 |
| Carson, CC | 1 |
| Ficorelli, CT; Weeks, B | 1 |
| Burhani, S; Harnett, JP; McLaughlin, TP; Mulhall, JP; Russell, D; Scott, B | 1 |
| Broderick, G; Cameron, A; Lockhart, D; Rosen, R; Shabsigh, R; Swindle, R | 1 |
| Corbin, J; Montorsi, F; Phillips, S | 1 |
| Pomeranz, HD | 1 |
| Hall, TA; McGwin, G; Owsley, C; Vaphiades, MS | 1 |
| Briganti, A; Gallina, A; Montorsi, F; Montorsi, P; Rigatti, P; Saccà, A; Salonia, A | 1 |
| Dyachkova, Y; Gatchalian, E; Glina, S; Kopernicky, V; Markey, C; Sotomayor, M; Yaman, O | 1 |
| Oguz, H; Verit, A | 1 |
| Agarwal, A; Nandipati, KC; Raina, R; Zippe, CD | 1 |
| Hedelin, H; Ljunggren, C; Ströberg, P | 1 |
| Minhas, S; Ralph, DJ; Wang, WF | 1 |
| Elkin, S | 1 |
| Wolfe, SM | 1 |
| Bivalacqua, TJ; Burnett, AL; Champion, HC; Musicki, B | 1 |
| Casariego, J; Cassinello, A; Lledó García, E; Mo, D; Rajmil, O; Rodríguez Vela, L | 1 |
| Adaikan, PG; Lau, LC | 1 |
| Cappelleri, JC; Sobel, RE | 1 |
| Chartier-Kastler, E; Denys, P; Previnaire, JG; Soler, JM | 1 |
| Flurer, RA; Gamble, BM; Gratz, SR | 1 |
| Beardsworth, A; Dean, J; Gentile, V; Hackett, GI; Pirozzi-Farina, F; Rosen, RC; Warner, MR; Zhao, Y | 1 |
| Ahuja, S; Broderick, GA; Donatucci, CF; Hatzichristou, D; Loughney, K; Sides, GD; Torres, LO; Valiquette, L; Zhao, Y | 1 |
| Kim, SC | 1 |
| Wooltorton, E | 1 |
| Prisant, LM | 1 |
| van Driel, MF | 1 |
| Brock, G; Chan, J; Chan, M; Dickson, R; Gagnon, R; Krisdaphongs, M; Lee, J; Mehta, P; Pommerville, P | 1 |
| Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Ke, H; Zoraghi, R | 1 |
| Campaña, JMC; Ciutat, LF; Miranda, EF; Tolrà, JR | 1 |
| Hatzichristou, D; Hatzimouratidis, K | 1 |
| Hütter, J; Sandner, P; Stelte-Ludwig, B; Tinel, H | 1 |
| Gopalakrishanan, G; Tharyan, P | 1 |
| Koh, HL; Low, MY; Oh, SS; Zou, P | 1 |
| Dinn, RB; Wall, M | 1 |
| Ahuja, S; Deeley, MC; Garcia, CS; Giuliano, F; Porst, H; Rosen, RC; Seftel, AD; Shabsigh, R | 1 |
| Beardsworth, A; Bertsch, J; Haro, JM; Kontodimas, S; Martin-Morales, A | 1 |
| Becker, AJ; Gratzke, C; Kedia, G; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Uckert, S | 1 |
| Beasley, A; Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Grimes, KA; Zoraghi, R | 1 |
| Ghofrani, HA; Grimminger, F | 1 |
| Brock, G; Carrier, S; Chan, J; Chan, M; Dickson, R; Gutkin, S; Horner, R; Klein, AH; Lang, C; Salgado, L | 1 |
| Gustafsson, LE; Hallén, K; Wiklund, NP | 1 |
| Kukreja, RC | 1 |
| Nini, A; Vardi, M | 1 |
| Grimsley, SJ; Jones, GE; Khan, MH | 1 |
| Bridge, S; Harnett, JP; Hvidsten, K; Kell, PD; Morant, SV | 1 |
| Geok-Mui, MK; Poh-Hoon, MC; Tay, EL; Yip, J | 1 |
| Abdel Aziz, AT; Abdel Aziz, MT; Atta, H; El-Shehaby, AM; Hassouna, AA; Marzouk, SA; Mostafa, T; Obaia, EM; Rashed, L; Sabry, D | 1 |
| Caglieresi, C; Canale, D; Francesca, F; Liguori, G; Macchia, E; Martino, E; Morelli, G; Moschini, C; Pomara, G; Selli, C; Turchi, P | 1 |
| Beardsworth, A; Chan, ML; Eardley, I; Jackson, G; Loughney, K; Mirone, V; Montorsi, F; Vail, GM | 1 |
| Biagioli, A; Caretta, N; Caretti, L; Foresta, C; Galan, A; Poletti, A; Zuccarello, D | 1 |
| Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Tilki, D; Uckert, S | 1 |
| Bischoff, E; Huetter, J; Neuser, D; Sandner, P; Stelte-Ludwig, B; Tinel, H; Ulbrich, E | 1 |
| Chodorowski, Z; Korolkiewicz, RP; Kozłowska-Boszko, B; Roszkowska-Kranc, K; Sein Anand, J; Tajanko, E | 1 |
| Barbieri, L; Briganti, A; Dehò, F; Gallina, A; Guazzoni, G; Montorsi, F; Rigatti, P; Saccà, A; Salonia, A; Suardi, N; Zanni, G | 1 |
| Beardsworth, A; Belger, M; Bertsch, J; Haro, JM; Hatzichristou, D; Martin-Morales, A; Riley, A; von Keitz, A; Wolka, AM | 1 |
| Chan, AY; Lai, CK; Lam, YH; Mak, TW; Poon, WT | 1 |
| Ahn, TY; Dwight, T; Dyachkova, Y; Kim, SW; Lee, MS; Lee, SW; Min, KS; Paick, JS; Park, K; Park, NC; Yang, DY | 1 |
| Ballanger, P; Calvet, C; Eftekhari, P; Farghal, H; Martin, K; Molimard, M; Moore, N; Robert, G | 1 |
| Corbin, JD; Francis, SH; Zoraghi, R | 2 |
| Hedelin, H; Ljunggren, C; Salomonsson, K; Ströberg, P | 1 |
| Atta, H; Aziz, AT; Aziz, MT; El-Shehaby, AM; Hassouna, AA; Marzouk, SA; Mostafa, T; Obaia, EM; Rashed, L; Sabry, D | 1 |
| Conaglen, HM; Conaglen, JV | 1 |
| Jonas, U; Kedia, G; Knapp, WH; Scheller, F; Sormes, M; Stief, CG; Uckert, S | 1 |
| Ghiadoni, L; Taddei, S; Versari, D | 1 |
| Antunes, E; De Nucci, G; Morganti, RP; Priviero, FB; Teixeira, CE; Toque, HA | 1 |
| Ali, ST | 1 |
| Antunes, JE; da Cunha, EF; Freitas, MP; Ramalho, TC; Rittner, R | 1 |
| Goda, Y; Haishima, Y; Hasegawa, T; Ishii, T; Kawahara, N; Nagata, T; Saijo, M | 1 |
| Antonialli, MM; Freitas, VM; Menezes, FG; Nascimento, JW | 1 |
| Antunes, E; Priviero, FB; Teixeira, CE; Toque, HA; Webb, RC; Zemse, SM | 1 |
| Sakuma, M; Shirato, K | 1 |
| De Berardis, G; Franciosi, M; Morelli, P; Nicolucci, A; Pamparana, F; Pellegrini, F; Tognoni, G | 1 |
| Buhse, LF; Gryniewicz, CM; Kauffman, JF; Reepmeyer, JC | 1 |
| Fusco, F; Mirone, V; Montorsi, F; Rossi, A; Sicuteri, R | 1 |
| Baldo, OB; Cartledge, J; Eardley, I; Storey, A; Taylor, J | 1 |
| Cecconi, F; Del Popolo, G; Lombardi, G; Macchiarella, A | 1 |
| Chan, CL; Dalan, R; Gardner, D; Kao, SL; Lee, KO; Lee, M; Lim, CC; Pratt, E; Tan, B | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Antoszyk, AN; Cordell, WH; Costigan, TM; Coupland, SG; Danis, RP; Klise, S; Marmor, MF; Maturi, RK; McGettigan, JW; Sides, GD; Weleber, RG | 1 |
| Antunes, E; Baracat, JS; Claudino, MA; De Nucci, G; Fregonesi, A; Priviero, FB; Teixeira, CE; Toque, HA | 1 |
| Gillatt, D; Gulur, DM; Mevcha, A; Persad, R | 1 |
| Chandrasekhar, SS; Maddox, PT; Saunders, J | 1 |
| De Orsi, D; Gagliardi, L; Gallinella, B; Marchei, E; Martufi, A; Nebuloni, P; Pellegrini, M; Pichini, S; Scaravelli, G | 1 |
| Prasad, B; Savaliya, AA; Shah, RP; Singh, S | 1 |
| Aversa, A; Balercia, G; Bocchio, M; Boscaro, M; Carani, C; Corona, G; Fabbri, A; Foresta, C; Forti, G; Francavilla, S; Granata, AR; Gravina, GL; Isidori, AM; Jannini, EA; Lenzi, A; Maggi, M; Mansani, R; Palego, P; Spera, G; Vetri, M | 1 |
| Abdo, CH; Gallagher, GL; Glina, S; Hernandez-Serrano, R; Lenero, E; Rampazzo, C; Rubio-Aurioles, E; Sotomayor, M; West, TM | 1 |
| Argiolas, A; Boi, A; Melis, MR; Sanna, F; Succu, S | 1 |
| Fusco, F; Haro, JM; Imbimbo, C; Kontodimas, S; Mirone, V; Rossi, A; Sicuteri, R | 1 |
| Katz, A | 2 |
| Shindel, AW | 1 |
| Badani, KK; Cheetham, P; Lee, DJ | 1 |
| Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; Natali, D; Price, LC; Savale, L; Simonneau, G; Sitbon, O | 1 |
| de Kaste, D; Venhuis, BJ; Vredenbregt, MJ; Zomer, G | 1 |
| Egawa, T; Ikeda, M; Kameyama, N; Kataoka, Y; Sejima, H; Shibuya, K; Shuto, H; Tominaga, K; Yamauchi, A | 1 |
| Harn, GL; Lajis, R; Man, CN; Nor, NM | 1 |
| Beardsworth, A; Fujita, K; Kato, M; Nakazawa, T; Sawamura, F | 1 |
| Chivers, ML; Rosen, RC | 1 |
| Borrull, F; Knepper, TP; Marcé, RM; Nieto, A; Peschka, M; Pocurull, E | 1 |
| Rosenzweig, EB | 1 |
| French, DD; Margo, CE | 1 |
| Gonenc, F; Ozgur, BC; Yazicioglu, AH | 1 |
| Berez, PB | 1 |
| Hill, LA; Hoel, G; MacDiarmid, SA; Volinn, W | 1 |
| Alvarez, LJ; Candia, OA; Gerometta, R | 1 |
| Heidelbaugh, JJ | 1 |
| Kopa, Z; Romics, I | 1 |
| Galiè, N; Rubin, LJ; Simonneau, G | 1 |
| Humbert, M; Jais, X; Sanchez, O; Simonneau, G; Sitbon, O | 1 |
| Einsele, H; Gattenlöhner, S | 1 |
| Martinac, AI; Milcić, N; Sokolić, M; Tomić, S | 1 |
| Harte, CB; Meston, CM | 1 |
| Bajramovic, S; Dzelaludin, J | 1 |
| Allmen, Hv; Chang, LL; Harper, K; Henderson, SC; Hornbuckle, K; Ma, M | 1 |
| Demirtas, A; Ekmekcioglu, O; Gökçe, A; Halis, F | 2 |
| Anzillotti, L; Botrè, F; de la Torre, X; Strano-Rossi, S | 1 |
| Chung, E | 1 |
| Ding, L; Huang, Z; Wang, M; Yan, H; Zhang, Y; Zhu, S | 1 |
| Akdag, E; Akyol, M; Haberal, A; Kayir, H; Kucukozkan, T; Oter, S; Ozdegirmenci, O; Topal, T; Uzbay, T | 1 |
| Chiap, P; Courselle, P; Crommen, J; De Beer, JO; De Beer, T; Deconinck, E; Sacré, PY; Vancauwenberghe, R | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N | 1 |
| Auerbach, PS; Grissom, CK; Hackett, PH; Luks, AM; McIntosh, SE; Rodway, GW; Schoene, RB; Zafren, K | 1 |
| Yuang, RQ | 1 |
| Kiliçkesmez, K; Küçükoğlu, MS | 1 |
| Ellor, N; Fujimoto, G; Plumb, RS; Skilton, SJ; Twohig, M | 1 |
| Csupor, D; Hohmann, J; Kecskeméti, A; Micsinay, A; Szekeres, A; Szendrei, K; Vékes, E; Veres, K | 1 |
| Jang, YM; Kim, CS; Kwon, SW; Lee, BJ; Lee, HM | 1 |
| Conaglen, HM; Conaglen, JV; McCabe, MP; O'Connor, EJ | 1 |
| Antelmi, A; Armani, A; Aversa, A; Brama, M; Calanchini, M; Caprio, M; Di Luigi, L; Fabbri, A; Francomano, D; Greco, EA; Lenzi, A; Migliaccio, S; Rosano, GM; Spera, G | 1 |
| Akgül, T; Ayyıldız, A; Germiyanoğlu, C; Huri, E; Ustün, H; Yagmurdur, H | 1 |
| Levin, YD; White, RJ | 1 |
| Hwang, EC; Kim, SO; Park, K | 1 |
| Corbin, JD; Francis, SH | 1 |
| Costabile, R; Lowe, G | 1 |
| Goldstein, I; Khera, M | 1 |
| Chiap, P; Courselle, P; Crommen, J; Daszykowski, M; De Beer, JO; Deconinck, E; Sacré, PY; Vancauwenberghe, R | 1 |
| Eisenreich, W; Schramek, N; Wollein, U | 1 |
| Banasiak, W; Inorowicz, E; Jankowska, EA; Josiak, K; Kremis, E; Ponikowski, P | 1 |
| Corona, G; Fusco, F; Mondaini, N; Razzoli, E; Rossi, A; Ungar, A | 1 |
| Bueno, MI; de Castro, EV; Limberger, RP; Mariotti, KC; Mayorga, P; Ortiz, RS; Rocha, WF; Romão, W; Sabin, GP; Schwab, NV | 1 |
| Costabile, RA; Lowe, G | 1 |
| Edvinsson, L; Gupta, S; Kruse, L; Kruuse, C; Nilsson, E | 1 |
| Helfand, BT; Mazur, DJ; McVary, KT | 1 |
| Beslać-Bumbaširević, L; Ercegovac, MD; Jovanović, DR; Stefanović-Budimkić, M | 1 |
| Brock, GB; Chung, E; DeRogatis, LR; Jannini, EA | 1 |
| Celso, M; Del Popolo, G; Lombardi, G; Mencarini, M; Nelli, F | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N; Wegener, G | 1 |
| Calderbank, M; Ivy, DD; Takatsuki, S | 1 |
| Carini, M; Corona, G; Gacci, M; Kaplan, SA; Maggi, M; McVary, KT; Mirone, V; Roehrborn, CG; Salvi, M; Serni, S; Vignozzi, L | 1 |
| Allanore, Y | 1 |
| Burns, P; Būttner, H; Hackett, G; Huynh, NN; Kim, ED; Kopernicky, V; Lenero, E; Montorsi, F; Morales, AM; Porst, H; Rubio-Aurioles, E; Stuckey, B; West, TM | 1 |
| de Kaste, D; Venhuis, BJ | 1 |
| Kotb, K; Mostafa, T; Rashed, L; Taymour, M | 1 |
| Chen, B; Chen, Z; Hu, JL; Huang, YR; Ma, Y; Wang, HX; Wang, YX; Xia, JG; Yang, Y | 1 |
| Andersen, ML; Cavalheiro, EA; Matos, G; Scorza, FA; Tufik, S | 1 |
| Barrio, RJ; Echeazarra, L; Goicolea, MA; Gómez-Caballero, A; Montaña, M; Sallés, J; Unceta, N | 1 |
| El-Demerdash, A; Lee, SJ; Song, F | 1 |
| Fujishige, K; Inoue, H; Kikkawa, K; Kobayashi, T; Kojima, K; Kotera, J; Mochida, H; Noto, T; Omori, K; Sasaki, T; Yamada, Y; Yee, S | 1 |
| Erkasap, N; Erkasap, S; Koken, T; Küçük, A; Ozkurt, M; Tosun, M; Yucel, M | 1 |
| Burnett, AL; Day, WW; DiDonato, K; Heller, WH; Kikkawa, K; Kotera, J; Omori, K; Peterson, CA; Wang, R; Yee, S | 1 |
| Cuadrado-Tejedor, M; Franco, R; García-Barroso, C; García-Osta, A; Goicolea, MA; Lanciego, JL; Oyarzabal, J; Pascual-Lucas, M; Rico, AJ; Ricobaraza, A; Sallés, J; Unceta, N | 1 |
| Ahmad, S; Brown, AW; Lemma, M; Nathan, SD; Shlobin, OA; Weir, N | 1 |
| Kass, DA | 1 |
| Shaeer, O | 1 |
| Bregel, D; Kaiser, R; Kraemer, T; Rust, KY; Wilkens, H; Wilske, J | 1 |
| Goldstein, I; Scranton, RE; Stecher, VJ | 1 |
| Burhenne, J; Haefeli, WE; Riedel, KD; Spalwisz, A; Theile, D; Weiss, J | 1 |
| Callahan, RJ; Dunn, JD; Gryniewicz-Ruzicka, CM; Mans, DJ | 1 |
| Miller, MS | 1 |
| Chen, Q; Ding, H; Lee, J; Liu, Y; Mao, C; Qin, X; Ren, Z; Tang, J; Tian, J; Yang, Z; Yuan, J; Zhang, R | 1 |
| Andersson, KE; Gratzke, C; Herlemann, A; Sievert, KD | 1 |
| Allanore, Y; Blaise, S; Caglayan, E; Carpentier, PH; Cracowski, JL; Roustit, M | 1 |
| Angulo, J; Chen, M; Cuevas, P; Fernández, A; González-Corrochano, R; La Fuente, J; Sáenz de Tejada, I | 1 |
| Deyo, RA; Dobscha, SK; Donovan, M; Johnson, ES; Morasco, BJ; Petrik, A; Smith, DH; Tillotson, CJ; Yang, X | 1 |
| Dotan, G; Krashin-Bichler, I | 1 |
| Borregales, L; Cairoli, C; Reyes, LA; Rubio-Aurioles, E; Sorsaburu, S | 1 |
| Al-Mitwalli, K; El-Meliegy, A; Gurbuz, S; Hussein, T; Istarabadi, M; Lei, Y; Mostafa, T; Rabah, D | 1 |
| de la Taille, A; Doridot, G; Giuliano, F; Rouprêt, M | 1 |
| Boehmer, M; Boess, FG; Büttner, H; Buvat, J; Hatzimouratidis, K; Henneges, C; Moncada, I; Vendeira, PA | 1 |
| Giessing, M; Neumann, NJ; Thierling, U; Uche-Holub, E | 1 |
| Chen, B; Hu, K; Huang, YR; Jin, Y; Ma, Y; Wang, HX; Wang, YX; Yang, H; Yang, Y | 1 |
| Chadwell, K; Fenkl, EA; Jones, SG; Patsdaughter, CA | 1 |
| Callanan, AC; Campbell, N; Clark, JP; Donnelly, BF; Goldstein, I; Kaminetsky, JC; Stecher, VJ; Thomas, JW | 1 |
| Du, Q; Gu, LX; Miao, Y; Pan, BC; Song, YS; Wu, B; Xing, X | 1 |
| Ge, X; Kee, CL; Koh, HL; Li, L; Low, MY; Patel, DN | 1 |
| Bullemor-Day, P; Chukwujekwu, C; Hawton, K; Lubin, J; Rudkin, L; Taylor, MJ | 1 |
| Abadi, AH; Chang, WC; Chen, X; Clapper, ML; Gary, BD; Grizzle, WE; Gurpinar, E; Keeton, AB; Li, N; Li, Y; Moyer, MP; Piazza, GA; Tinsley, HN; Xi, Y; Zhu, B | 1 |
| Criscuolo, E; DellaGreca, M; Isidori, M; Lavorgna, M; Pistillo, P; Previtera, L; Russo, C; Temussi, F; Zarrelli, A | 1 |
| Burns, PR; Goldfischer, ER; Kim, ED; Ni, X; Seftel, AD | 1 |
| Doran, AK; Hill, W; Shapiro, S; Traiger, G; Zhang, L | 1 |
| Gao, L; Hong, K; Jiang, H; Liu, DF; Ma, LL; Mao, JM; Qiao, J; Tang, WH; Yang, Y; Zhang, J; Zhao, LM; Zhuang, XJ | 1 |
| Mirzaii-Dizgah, I; Salmanyan, B | 1 |
| Corte-Real, F; Franco, JM; Marcos, M; Mustra, C; Proença, P; Vieira, DN | 1 |
| He, Q; Jiang, X; Jin, J; Li, J; Shen, J; Terrett, NK; Tian, G; Wang, Z; Wu, H; Yang, B; Yang, X; Zhu, D | 1 |
| Chaumais, MC; Humbert, M; Montani, D; Perrin, S; Simonneau, G; Sitbon, O | 1 |
| Cho, S; Han, KM; Kim, NS; Kim, SH; Kim, WS; Lee, JH | 1 |
| Cai, YH; Feng, LJ; Huang, YY; Li, X; Li, Z; Luo, HB; Wu, Y | 1 |
| Beheshtian, E; Sabri, MR | 1 |
| Channick, R; Klinger, JR; Preston, I | 1 |
| Ioakeimidis, N; Kostis, JB | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Bretsztajn, L; Eardley, I; Mohee, A; Storey, A | 1 |
| Cui, H; Deng, Y; Fang, J; Liu, B; Song, Z; Wang, H; Wang, Z; Zhang, S | 1 |
| Adams, JL; Cook, MB; Finkle, WD; Frasco, MA; Fraumeni, JF; Greenland, S; Hoover, RN; Ridgeway, GK | 1 |
| Aoyama, A; Asada, A; Doi, T; Kajimura, K; Sawabe, Y; Tagami, T; Takeda, A | 1 |
| Behr, J; Geiseler, J; Huppmann, P; Ihle, F; Leuchte, HH; Meis, T; Neurohr, C; Tufman, A; von Wulffen, W; Zimmermann, GS | 1 |
| Watanabe, H | 1 |
| Apers, S; Canfyn, M; Courselle, P; Custers, D; De Beer, JO; Deconinck, E | 1 |
| Bourge, RC; Burger, CD; Durst, L; Franco, V; Frantz, RP; McDevitt, S; Oudiz, RJ; Walker, S; Waxman, AB | 1 |
| Kamata, Y; Minota, S | 1 |
| Elashoff, RM; Miceli, MC; Nelson, MD; Nelson, SF; Rader, F; Sweeney, HL; Tang, X; Tavyev, J; Victor, RG | 1 |
| Alkan, F; Erturkuner, P; Ozbek, E; Simsek, A; Tasci, AI; Tugcu, V | 1 |
| Angulo, J; Cardoso, J; Cuevas, P; Fernández, A; La Fuente, JM; Martínez-Salamanca, JI; Wright, HM | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Cleary, KL; Običan, SG | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Poklepovic, A; Roberts, JL | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE | 1 |
| Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Lasker, GF; Pankey, EA; Sikka, SC | 1 |
| Hsu, JC; Lu, CY; Tang, DH | 1 |
| Egenlauf, B; Ehlken, N; Grünig, E; Harzheim, D; Lichtblau, M; Marra, A; Pinado, FP | 1 |
| Faria, AP; Modolo, R; Moreno, BV; Moreno, H | 1 |
| Athyros, V; Doumas, M; Katsiki, N; Lazaridis, A | 1 |
| Baygani, S; Burns, P; Goldfischer, E; Kim, E; Seftel, A | 1 |
| Booth, L; Cash, DR; Cornelissen, CN; Cruz-Luna, T; Cycon, KA; Dent, P; Fidanza, A; Jean, S; Roberts, JL; Siembiba, P; Tavallai, S | 1 |
| Ala, S; Babazadeh, K; Rafati, M; Saeedi, M; Shiran, M; Shiva, A; Zamani, H | 1 |
| Cui, Y; Gao, Z; Liu, X; Shi, L | 1 |
| Hirono, K; Ichida, F; Kohno, H; Nakamura, S; Nakamura, T; Ozawa, S; Taguchi, M; Takahiro, R; Yoshimura, N | 1 |
| Bentley, S; Magee, AG; Makhecha, S | 1 |
| Bulotta, S; Celano, M; Damante, G; De Rose, RF; Di Gioia, CR; Durante, C; Filetti, S; Giacomelli, L; Maggisano, V; Pecce, V; Rosignolo, F; Russo, D; Sponziello, M; Verrienti, A | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Iannino-Renz, R; Mager, D | 1 |
| Can, B; Çerkez, C; Ergün, H; Göktürk, H; Işılgan, SE; Kaya, B; Serel, S; Yığman, Z | 1 |
| ElAgouri, G; ElAmrawy, F; ElYazbi, A; Eshra, A; Nounou, MI | 1 |
| Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T | 1 |
| Arıkan, M; Ekşioğlu, MF; Hesar, RH; Korkusuz, P; Toğral, G | 1 |
| Singman, EL; van Landingham, SW | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Blouin, J; Coyle, D; Coyle, K; Innes, M; Jabr, MF; Lee, K; Mielniczuk, L; Swiston, J; Tran, K | 1 |
| Hu, T; Kang, M; Qu, X; Song, Q; Yang, L; Zhang, D; Zhao, Y | 1 |
| Jujo, T; Kasai, H; Kato, F; Nishimura, R; Sakao, S; Sekine, A; Shigeta, A; Suda, R; Sugiura, T; Tanabe, N; Tatsumi, K | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Bakırdere, S; Fidan, AK | 1 |
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| Echeverría-García, F; García-Perdomo, HA; Tobías, A | 1 |
| Deng, L; Han, P; Liu, L; Qiu, S; Tang, Z; Wei, Q; Yang, L | 1 |
| Hassan, M; Sheweita, SA; Wally, M | 1 |
| Li, AS; Pomeranz, HD | 1 |
| Egberts, TC; Heerdink, ER; Janssen, DG; Vermetten, E | 1 |
| Anzanello, MJ; Ferrão, MF; Fogliatto, FS; Marcelo, M; Mariotti, K; Ortiz, RS; Yamashita, G | 1 |
| Mostafa, T | 1 |
| Al Busaidi, I; Al Lawati, HA; Kadavilpparampu, AM; Suliman, FO | 1 |
| Liu, L; Tan, P; Tang, Z; Wei, Q; Wei, S; Yang, L | 1 |
| Gamidov, SI; Izhbaev, SK; Ovchinnikov, RI; Popova, AY | 1 |
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Coelho Neto, J; Lisboa, FLC | 1 |
| Gong, B; Huang, J; Huang, Y; Luo, Y; Ma, M; Sun, T; Xie, W; Yang, X | 1 |
| Bajraktari, G; Bugert, P; Burhenne, J; Haefeli, WE; Weiss, J | 1 |
| Ahmadi, A; Bigdelian, H; Ghaderian, M; Hosseinzadeh, M; Sabri, MR; Shoja, M | 1 |
| Thenappan, T; Weir, EK | 1 |
| Bonnet, S; Lepièce, G; Smal, C | 1 |
| Mostafa, RE; Omara, EA; Salama, A | 1 |
| Cracowski, JL; Humbert, M; Khouri, C; Lepelley, M; Montastruc, F; Roustit, M | 1 |
| Frankenreiter, S; Friebe, A; Groneberg, D; Krieg, T; Kuret, A; Lukowski, R; Ruth, P | 1 |
| Hassan, TA; Mulhall, JP; Rienow, J | 1 |
| Chang, M; Gall, H; Grünig, E; Halank, M; Mielniczuk, L; Orozco-Levi, M; Tanabe, N; Vachiéry, JL; Vogtländer, K | 1 |
| Bala Divya, M; Dash, P; Guruprasad, K; Guruprasad, L | 1 |
| Estrada, SM; Ieronimakis, N; Napolitano, PG; Reed, LC; Schmiedecke, SS; Villazana-Kretzer, DL; Walton, RB | 1 |
| Tanabe, N | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Anzanello, MJ; Chaovalitwongse, WA; Ferrão, MF; Fogliatto, FS; Kahmann, A; Marcelo, MCA; Mariotti, KC; Ortiz, RS | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| De Alba, F; Kaja, S; Rosen, SM | 1 |
| Bydlowski, SP; Clavé, MM; Lopes, AA; Maeda, NY; Thomaz, AM | 1 |
| Bakırdere, S; Özbek, B; Öztürk Er, E | 1 |
| Cohen, JL; Krishnan, US; Nees, SN; Rosenzweig, EB; Valencia, GA | 1 |
| Anzanello, MJ; de Araújo Gomes, A; de Cassia Mariotti, K; Dos Santos, MK; Ferrão, MF; Kahmann, A; Limberger, RP; Ortiz, RS | 1 |
| Comerma-Steffensen, S; Knudsen, JS; Munk, NE; Simonsen, U | 1 |
| Fan, H; Fu, C; Luo, L; Wang, K; Xie, X; Yue, Z; Zeng, H; Zhang, W; Zhang, Y | 1 |
| Bhattacharya, SK; Gulati, K; Gupta, R; Laxmi, V; Ray, A | 1 |
| Anzanello, MJ; Ferrão, MF; Fogliatto, FS; Mariotti, KC; Ortiz, RS; Soares, F | 1 |
| Arnold, DG; Oakley, JL | 1 |
| Kang, H; Lee, JH; Lee, YM; Park, HN; Park, S | 1 |
| Cari, L; Costantini, E; Illiano, E; Kopa, Z; Nocentini, G; Petrillo, MG; Scroppo, FI; Silvani, M; Zucchi, A | 1 |
| Bender, SB; Jaffey, JA; Kong, LR; Leach, SB; Reinero, CR; Wiggen, KE | 1 |
| Ding, S; Huang, X; Liu, L; Song, G; Wang, D; Xu, H | 1 |
| Kimura, K; Matsushita, R; Tsuboi, H; Yoshida, N; Zhu, S | 1 |
| Griffiths, A; Hadley, L | 1 |
| Akalın, EE; Anğın, AD; Basak, K; Cikman, MS; Kaptanagasi, AO; Sakin, O | 1 |
| Dhaun, N; Farrah, TE; Tzoumas, N; Webb, DJ | 1 |
| Albulescu, D; Buga, AM; Burada, F; Calina, D; Ciurea, ME; Docea, AO; Iordache, AM; Mamoulakis, C; Mitrut, R; Rogoveanu, OC; Sosoi, S; Tsatsakis, A; Vasile, RC; Zlatian, O | 1 |
| Cai, Z; Li, H; Ma, C; Zhang, J | 1 |
| Chopra, I; Hassan, TA; Mulhall, JP; Patel, D; Tang, WY | 1 |
| El-Hajjar, M; Kumar, S; Zheng, WQ | 1 |
| Jia, DH; Li, R; Wang, CL; Wang, R; Yang, F; Zhang, TB; Zhang, WX; Zheng, T | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Cheng, Q; Shi, S; Wu, Y; Zhou, M | 1 |
| Cai, Z; Li, H; Ma, C; Xiong, J; Zhang, J | 1 |
| Li, C; Moezzi, B; Xu, D | 1 |
| Hong, J; Kim, BH; Kim, HJ; Lee, JH; Lee, ME; Lee, W; Lee, YM; Oh, HB; Park, S | 1 |
| Cho, HD; Eom, HY; Ha, N; Han, SB; Kang, MH; Kim, G; Kim, J; Kim, U; Koo, HR; Seo, S; Song, UT; Suh, JH | 1 |
| Cummings, TH; Hardin, JW; Magagnoli, J; Sutton, SS | 1 |
| Gross, MS; Rezaee, ME | 1 |
| Albulescu, D; Buga, AM; Calina, D; Docea, AO; Georgiadis, G; Iordache, AM; Mamoulakis, C; Mitrut, R; Tsatsakis, A; Vasile, RC; Zisis, IE | 1 |
| Dal Moro, F; Livi, U; Vendramin, I | 1 |
| De Nunzio, C; Lombardo, R; Tema, G | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Fernandes, C; Fialho, SL; Gloria, MBA; Oliveira Andrade, MV; Paula, WX; Pianetti, GA; Reis, NFA; Silva, LFG; Souza Moreira, CP; Souza, MACE | 1 |
| Balbaa, ME; Meftah, AA; Sheweita, MS; Sheweita, SA | 1 |
| Shi, J; Song, LL; van den Anker, J; Wu, YE; Yang, XY; Zhang, W; Zhao, W | 1 |
| Chhonker, SK; Koiri, RK; Rawat, D | 2 |
| Chiba, F; Iwase, H; Nagasawa, S; Saka, K; Torimitsu, S; Yajima, D; Yamagishi, Y; Yamaguchi, R | 1 |
| Ashok, R; Dai, YT; Gao, QQ; Song, T; Sun, GH; Sun, XL; Xu, ZP; Yu, W | 1 |
| Bai, L; Liu, J; Wang, L; Wu, Q; Zhang, H | 1 |
| Haidich, AB; Hatzichristodoulou, G; Hatzichristou, D; Mykoniatis, I; Ouranidis, A; Pyrgidis, N; Sokolakis, I; Sountoulides, P; van Renterghem, K | 1 |
| Bernardes, GJS; d'Acampora, AJ; Lombardi, T; Martinelli-Kläy, CP; Sgrott, SM; Souza, LAC; Souza, RAC; Sudbrack, TR | 1 |
| Baek, SY; Han, JH; Kim, H; Lee, JH; Min, AY; Park, OR; Yang, YJ | 1 |
| Baek, JW; Eum, JH; Heo, Y; Her, YS; Kim, DS; Oh, MH; Shin, DH; Song, SH; Sung, S | 1 |
| Kimura, K; Sanada, T; Tsuboi, H; Yoshida, N | 1 |
| Allazov, SA; Gafarov, RR; Giyasov, SI; Shodmonova, ZR | 1 |
| Buchner, A; Gratzke, C; Rodler, S; Schröder, F; Stief, C; von Büren, J; von Büren, M; Wiesenhütter, I; Wülfing, C | 1 |
| Cheng, YB; Guo, JL; He, Y; Li, S; Sun, L; Tang, Y; Wang, J; Wang, YL; Xin, Y; Zeng, HQ; Zhang, YP; Zhu, ZH | 1 |
| Anzanello, MJ; Fontes, JA; Gonçalves de Brito, JB; Mariotti, K; Ortiz, RS; Puglia, FDP; Scharcanski, J | 1 |
| Barbagallo, F; Casarini, L; D'Alessandro, S; Di Rocco, G; Guerrini, R; Lazzaretti, C; Limoncella, S; Pacifico, S; Paradiso, E; Santi, D; Simoni, M; Sola, M; Tagliavini, S; Trenti, T | 1 |
| Alghobary, MF; Mostafa, T | 1 |
| Deprest, J; Kumar, S; Mol, BW; Russo, F; Turner, JM | 1 |
| Al-Majed, AA; Alshehri, YM; Attwa, MW; Bakheit, AH | 1 |
| Brevik, A; El-Khatib, F; Jenkins, LC; Loeb, CA; Schneider, D; Yafi, FA | 1 |
| Skoularigis, J; Starling, RC; Triposkiadis, F; Xanthopoulos, A | 1 |
| Baek, SY; Han, JH; Jung, EJ; Kim, NS; Lee, JH; Park, OR; Yang, YJ | 1 |
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Forootanfar, H; Hamzehnejadi, M; Homayouni, F; Jahani, Z; Langarizadeh, MA; Rezaei, M; Tavakoli, MR | 1 |
| Al-Hemyari, SS; Ibrahim, B; Jairoun, AA; Shahwan, M; Zyoud, SH | 1 |
| Adam, V; Markova, K; Mravec, F; Nejdl, L; Pavelicova, K; Rypar, T; Vaculovicova, M | 1 |
| Humbert, M; Weatherald, J | 1 |
| Abbasi, B; Breyer, BN; Hakam, N; Lui, JL; Shaw, NM | 1 |
| Buendía, JA; Guerrero Patiño, D; Lindarte, EF | 1 |
| Montorsi, F; Salonia, A; Ventimiglia, E | 1 |
| Brookman-May, SD; Gratzke, C; von Büren, J; von Büren, M; Wülfing, C | 1 |
| Fadaei, S; Forootanfar, H; Jahani, Z; Langarizadeh, MA; Nejad, BG; Salary, A; Tavakoli, MR | 1 |
| Afsharrezaei, F; Bahri, RA; Gholami, M; Shafiee, A; Teymouri Athar, MM | 1 |
| Anghel, DM; Baconi, DL; Chițescu, CL; Ciobanu, AM; Costea, GV; Gheorghiu, ORC; Guțu, CM; Vlasceanu, AM | 1 |
| Armin, A; Khoshdel, AR; Poopak, A; Samzadeh, M; Zahir, M | 1 |
| Baker, PN; Ganzevoort, W; Gluud, C; Groom, KM; Jakobsen, JC; Kariya, CT; Kenny, LC; Leemhuis, AG; Magee, LA; Mol, BWJ; Papageorghiou, AT; Pels, A; Sharp, AN; von Dadelszen, P | 1 |
| Caglayan, MO; Üstündağ, İ | 1 |
| Cellek, S; Ilg, MM; Megson, M; Ralph, DJ | 1 |
| Henry, DS; Pellegrino, RG | 1 |
| Chess-Williams, R; Nilsson, D; Sellers, D | 1 |
| Argenziano, G; Brancaccio, G; Briatico, G; Capone, F; Cilio, S; Crocetto, F; Ferro, M; Imbimbo, C; Salonia, A | 1 |
| Azevedo, JEC; de Araujo, DB; de Mello, VJ; Favacho Lopes, DC; Hamoy, AO; Hamoy, M; Martins Rodrigues, JC; Nascimento, CP; Silva, ALMD; Tiago, ACDS; Vieira, LR | 1 |
110 review(s) available for tadalafil and sildenafil citrate
| Article | Year |
|---|---|
Phosphodiesterase 5 inhibitors: current status and potential applications.
Topics: Carbolines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Structure-Activity Relationship; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2002 |
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Contraindications; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Prevalence; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2002 |
Pharmacological management of erectile dysfunction.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Carbolines; Drug Combinations; Erectile Dysfunction; Humans; Imidazoles; Injections; Male; Papaverine; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2003 |
The phosphodiesterase inhibitor 'war'.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Patient Compliance; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
[How effective are PDE-5 inhibitors?].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Imidazoles; Male; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2003 |
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Topics: Carbolines; Clinical Trials as Topic; Cyclic GMP; Erectile Dysfunction; Female; Humans; Imidazoles; Male; Muscle, Smooth; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2002 |
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
Oral drug treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Apomorphine; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
[Pleasure and pain in sexual relations. The basis and reasons for sex counseling by the general practitioner].
Topics: Adult; Carbolines; Erectile Dysfunction; Family Practice; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Physician-Patient Relations; Piperazines; Purines; Risk Factors; Sex Counseling; Sex Factors; Sexual Dysfunction, Physiological; Sexuality; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2003 |
Treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Molecular Structure; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vacuum; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
[Treatment of erectile dysfunction].
Topics: Adrenergic alpha-Antagonists; Androgens; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phytotherapy; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Yohimbine | 2004 |
Emerging oral drugs for erectile dysfunction.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Apomorphine; Carbolines; Comorbidity; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dopamine Agonists; Double-Blind Method; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Second Messenger Systems; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Rate; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Substrate Specificity; Sulfones; Tachycardia; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation; Vision, Ocular | 2004 |
[Old and new treatments of erectile dysfunction].
Topics: Administration, Oral; Adult; Carbolines; Combined Modality Therapy; Erectile Dysfunction; Finland; Follow-Up Studies; Humans; Injections, Intralesional; Male; Middle Aged; Piperazines; Purines; Risk Assessment; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2004 |
New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Diabetes Complications; Drug Interactions; Humans; Imidazoles; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Arteriosclerosis; Blood Pressure; Carbolines; Contraindications; Coronary Disease; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Endothelium, Vascular; Erectile Dysfunction; Heart Rate; Humans; Hypotension; Imidazoles; Isosorbide Dinitrate; Male; Molecular Structure; Myocardial Infarction; Nitric Oxide Donors; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2004 |
Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
Erectile dysfunction.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Patient Selection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
Topics: Carbolines; Controlled Clinical Trials as Topic; Cross-Over Studies; Erectile Dysfunction; Humans; Imidazoles; Male; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Clinical monograph for drug formulary review: erectile dysfunction agents.
Topics: Carbolines; Drug Information Services; Erectile Dysfunction; Formularies as Topic; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
[Erectile dysfunction (ED) and diabetes mellitus].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Complications; Diabetic Neuropathies; Diagnosis, Differential; Erectile Dysfunction; Humans; Imidazoles; Male; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Topics: Administration, Oral; Alprostadil; Apomorphine; Carbolines; Constriction; Contraindications; Dopamine Agonists; Drug Combinations; Enzyme Inhibitors; Erectile Dysfunction; Humans; Imidazoles; Male; Papaverine; Patient Satisfaction; Penile Prosthesis; Penis; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Regional Blood Flow; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Biological Availability; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytochrome P-450 CYP3A; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Metabolic Clearance Rate; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Patient Education as Topic; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Safety; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2005 |
[Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatectomy; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
PDE-5 inhibitors: current status and future trends.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Forecasting; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Optic Disk; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Blood Pressure; Carbolines; Clinical Trials as Topic; Coronary Artery Disease; Cyclic Nucleotide Phosphodiesterases, Type 5; Electrophysiology; Erectile Dysfunction; Heart Rate; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Ejaculation; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; RNA, Messenger; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Triazines; Urogenital System; Vardenafil Dihydrochloride | 2004 |
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
Topics: Administration, Oral; Aged; Algorithms; Alprostadil; Carbolines; Combined Modality Therapy; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Penile Prosthesis; Phosphodiesterase Inhibitors; Piperazines; Practice Guidelines as Topic; Prostatectomy; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Ejaculation; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2006 |
Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Blood Pressure; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hypertension; Hypotension; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vascular Resistance | 2006 |
[Phosphodiesterase inhibitors: effectiveness and new applications].
Topics: Carbolines; Coronary Disease; Erectile Dysfunction; Humans; Hypertension; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
Phosphodiesterase type 5 inhibitors: the day after.
Topics: Animals; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Erectile dysfunction.
Topics: Adult; Alprostadil; Apomorphine; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Penile Erection; Penile Prosthesis; Piperazines; Purines; Sex Counseling; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Yohimbine | 2006 |
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetic Angiopathies; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Phosphodiesterase 5 inhibition in essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Carbolines; Endothelium; Humans; Hypertension; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Topics: Carbolines; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Quality of Life; Self Concept; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Reproduction; Sildenafil Citrate; Spinal Cord Injuries; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride; Young Adult | 2009 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
Penile rehabilitation.
Topics: Alprostadil; Carbolines; Causality; Clinical Protocols; Erectile Dysfunction; Fibrosis; Humans; Male; Nurse's Role; Penile Prosthesis; Penis; Phosphodiesterase Inhibitors; Piperazines; Postoperative Care; Prostatectomy; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Vasodilator Agents | 2009 |
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Topics: Algorithms; Carbolines; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
Topics: Animals; Carbolines; Clitoris; Female; Humans; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sex Factors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vagina; Vardenafil Dihydrochloride; Women's Health | 2010 |
Tadalafil for the treatment of pulmonary arterial hypertension.
Topics: Carbolines; Erectile Dysfunction; Half-Life; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
Management of erectile dysfunction.
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Factors; Risk Reduction Behavior; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
[Guidelines for the diagnosis and treatment of pulmonary hypertension].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Piperazines; Practice Guidelines as Topic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Topics: Carbolines; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2010 |
Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbolines; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Kidney; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2011 |
Prevalence and medical management of erectile dysfunction in Asia.
Topics: Adult; Aged; Asia; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prevalence; Purines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Phosphodiesterase type 5 inhibitor abuse: a critical review.
Topics: Carbolines; Drug Contamination; Humans; Imidazoles; Internet; Marketing; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Substance-Related Disorders; Sulfones; Tadalafil; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2011 |
Erectile dysfunction.
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Phosphodiesterase Inhibitors; Prostatectomy; Sildenafil Citrate; Tadalafil | 2011 |
[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].
Topics: Carbolines; Heart Failure; Humans; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2011 |
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Topics: Algorithms; Carbolines; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Imidazoles; Impotence, Vasculogenic; Male; Men's Health; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Carbolines; Disease Progression; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Men's Health; Middle Aged; Neurotransmitter Agents; Piperazines; Prognosis; Prostatic Hyperplasia; Purines; Receptors, Neurotransmitter; Risk Assessment; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2012 |
Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Topics: Carbolines; Central Nervous System Diseases; Clinical Trials as Topic; Humans; Imidazoles; Impotence, Vasculogenic; Male; Multiple Sclerosis; Parkinson Disease; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Spinal Dysraphism; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks.
Topics: Carbolines; Chemistry Techniques, Analytical; Cyclic Nucleotide Phosphodiesterases, Type 5; Dietary Supplements; Drug Contamination; Erectile Dysfunction; Humans; Imidazoles; Ions; Male; Models, Chemical; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2012 |
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.
Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling | 2012 |
Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
Topics: 5-alpha Reductase Inhibitors; Affect; Antidepressive Agents; Antihypertensive Agents; Carbolines; Comorbidity; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Long-Term Care; Male; Medication Adherence; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Self Concept; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2013 |
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Resistance; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostate; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2013 |
Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Topics: Administration, Oral; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Odds Ratio; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Risk Assessment; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2013 |
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Topics: Carbolines; Controlled Clinical Trials as Topic; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Urodynamics; Vardenafil Dihydrochloride | 2013 |
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
Topics: Carbolines; Humans; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Raynaud Disease; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2013 |
[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Topics: Carbolines; Chemistry Techniques, Analytical; Drug Contamination; Humans; Imidazoles; Pharmaceutical Preparations; Phosphodiesterase 5 Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2014 |
Strategies for managing sexual dysfunction induced by antidepressant medication.
Topics: Antidepressive Agents; Bupropion; Carbolines; Drug Substitution; Female; Humans; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sex Factors; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Topics: Adult; Animals; Carbolines; Child; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Topics: Administration, Oral; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Topics: Animals; Carbolines; Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2014 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.
Topics: Carbolines; Diastole; Drug Resistance; Heart Failure, Diastolic; Humans; Hypertension; Medical Illustration; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
PDE-5 inhibitors: clinical points.
Topics: Cardiovascular Diseases; Drug Incompatibility; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; Vasodilator Agents | 2015 |
Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Topics: Erectile Dysfunction; Humans; Male; Organ Sparing Treatments; Peripheral Nerves; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Prostatectomy; Pyrimidines; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vardenafil Dihydrochloride | 2016 |
Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Topics: Animals; Child; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2015 |
Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Randomized Controlled Trials as Topic; Sildenafil Citrate; Spinal Cord Injuries; Tadalafil; Treatment Outcome; Vardenafil Dihydrochloride; Young Adult | 2017 |
Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Topics: Adolescent; Adult; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatectomy; Prostatic Neoplasms; Sildenafil Citrate; Tadalafil; Treatment Outcome; Young Adult | 2016 |
Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Topics: Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vardenafil Dihydrochloride | 2016 |
The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review.
Topics: Administration, Oral; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sperm Count; Sperm Motility; Spermatozoa; Tadalafil; Vardenafil Dihydrochloride | 2017 |
[Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2017 |
Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Topics: Back Pain; Controlled Clinical Trials as Topic; Erectile Dysfunction; Flushing; Humans; Male; Myalgia; Patient Preference; Phosphodiesterase 5 Inhibitors; Self Efficacy; Sildenafil Citrate; Tadalafil | 2017 |
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Pharmacovigilance; Phosphodiesterase 5 Inhibitors; Pulmonary Wedge Pressure; Sildenafil Citrate; Tadalafil; World Health Organization | 2018 |
Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Topics: Administration, Oral; Alprostadil; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Penile Erection; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Treatment Failure; Treatment Outcome; Vasodilator Agents | 2019 |
The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Topics: Administration, Mucosal; Adult; Aged; Aged, 80 and over; Erectile Dysfunction; Humans; Male; Middle Aged; Mouth Mucosa; Patient Compliance; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Quality of Life; Sexual Behavior; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2019 |
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Flavonoids; Humans; Neurons; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Purinones; Pyrimidines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride | 2019 |
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
Topics: Cardiovascular Diseases; Erectile Dysfunction; Humans; Hypertension; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2020 |
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Topics: Bayes Theorem; Databases, Factual; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Safety; Sildenafil Citrate; Tadalafil; Tamsulosin; Treatment Outcome | 2020 |
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Priapism; Sildenafil Citrate; Tadalafil | 2020 |
Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatectomy; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2021 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Oral drugs used to treat persistent pulmonary hypertension of the newborn.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Humans; Infant, Newborn; Off-Label Use; Persistent Fetal Circulation Syndrome; Randomized Controlled Trials as Topic; Sildenafil Citrate; Tadalafil | 2020 |
Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Combined Modality Therapy; Drug Therapy, Combination; Equipment and Supplies; Erectile Dysfunction; Extracorporeal Shockwave Therapy; Folic Acid; Humans; Hypoglycemic Agents; Male; Metformin; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vitamin B Complex | 2021 |
Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2022 |
Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Topics: Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Fetal Distress; Fetal Growth Retardation; Humans; Hypertension, Pulmonary; Infant, Newborn; Phosphodiesterase 5 Inhibitors; Pregnancy; Sildenafil Citrate; Tadalafil | 2022 |
Lodenafil.
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2022 |
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Topics: Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Guanosine Monophosphate; Guanylate Cyclase; Heart Failure; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Retrospective Studies; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Vasodilator Agents | 2022 |
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review.
Topics: Alprostadil; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Prostaglandins; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2022 |
An overview of the history, current strategies, and potential future treatment approaches in erectile dysfunction: a comprehensive review.
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Quality of Life; Sildenafil Citrate; Tadalafil; United States | 2023 |
Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
Topics: Cyclic Nucleotide Phosphodiesterases, Type 5; Esophageal Achalasia; Humans; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2023 |
Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy.
Topics: Female; Fetal Death; Fetal Growth Retardation; Humans; Infant, Newborn; Nitric Oxide; Nitroglycerin; Placenta; Pregnancy; Premature Birth; Sildenafil Citrate; Tadalafil | 2023 |
The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.
Topics: Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Skin Neoplasms; Tadalafil; Vardenafil Dihydrochloride | 2023 |
38 trial(s) available for tadalafil and sildenafil citrate
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2003 |
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Carbolines; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Patient Satisfaction; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Sweden; Tadalafil | 2003 |
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.
Topics: Adult; Aged; Carbolines; Cross-Over Studies; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2004 |
Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Penile Erection; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Spinal Cord Injuries; Sulfones; Tadalafil; Time Factors; Vasodilator Agents | 2004 |
Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Luteinizing Hormone; Male; Middle Aged; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone | 2004 |
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Oxygen; Phosphoric Diester Hydrolases; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vascular Resistance; Vasodilator Agents | 2004 |
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
Topics: Adolescent; Adult; Aged; Carbolines; Cross-Over Studies; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; United Kingdom | 2005 |
Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Coitus; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Penile Erection; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2006 |
[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study].
Topics: Adult; Aged; Carbolines; Double-Blind Method; Erectile Dysfunction; Europe; Humans; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; United States | 2006 |
Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
Topics: Adult; Analysis of Variance; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Reaction Time; Retrospective Studies; Sildenafil Citrate; Spinal Cord Injuries; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
Topics: Adult; Aged; Analysis of Variance; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Self Concept; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2006 |
Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Topics: Aged; Carbolines; Coitus; Cross-Over Studies; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Quality of Life; Severity of Illness Index; Sexual Behavior; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Remission Induction; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride | 2007 |
Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Carbolines; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Depression, Chemical; Double-Blind Method; Humans; Infertility, Male; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sperm Motility; Stimulation, Chemical; Sulfones; Tadalafil | 2007 |
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Topics: Adolescent; Adult; Aged; Carbolines; Cross-Over Studies; Erectile Dysfunction; Humans; Logistic Models; Male; Middle Aged; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2007 |
Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects.
Topics: Adult; Blood Flow Velocity; Blotting, Western; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Ophthalmic Artery; Phosphodiesterase Inhibitors; Piperazines; Purines; Retina; Sildenafil Citrate; Statistics as Topic; Sulfones; Tadalafil; Time Factors | 2008 |
[PDE5 inhibitors in treatment of benign prostatic syndrome].
Topics: Animals; Carbolines; Cell Division; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Isometric Contraction; Male; Middle Aged; Muscle, Smooth; Organ Culture Techniques; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Prostate; Prostatic Hyperplasia; Purines; Rats; Sildenafil Citrate; Stromal Cells; Sulfones; Syndrome; Tadalafil; Triazines; Urethra; Urinary Bladder; Vardenafil Dihydrochloride | 2007 |
Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
Topics: Adult; Aged; Carbolines; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Korea; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Psychology; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2007 |
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.
Topics: Carbolines; Cross-Over Studies; Erectile Dysfunction; Female; Humans; Male; Middle Aged; Personal Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sexual Partners; Sildenafil Citrate; Sulfones; Tadalafil | 2008 |
Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Topics: Administration, Oral; Adult; Carbolines; Coitus; Erectile Dysfunction; Humans; Male; Middle Aged; Orgasm; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Saudi Arabia; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2008 |
Retinal effects of 6 months of daily use of tadalafil or sildenafil.
Topics: Adult; Aged; Carbolines; Double-Blind Method; Electroretinography; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Retina; Sildenafil Citrate; Sulfones; Tadalafil | 2009 |
The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Topics: Analysis of Variance; Carbolines; Confidence Intervals; Cross-Over Studies; Health Surveys; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk; Sildenafil Citrate; Statistics as Topic; Sulfones; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride | 2009 |
Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study.
Topics: Analysis of Variance; Asia; Australia; Carbolines; Coitus; Confidence Intervals; Europe; Geography; Health Status Indicators; Humans; Impotence, Vasculogenic; Latin America; Male; Middle Aged; Middle East; New Zealand; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors | 2009 |
Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Cross-Over Studies; Drug Interactions; Humans; Indoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Posture; Purines; Receptors, Adrenergic, alpha-1; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study.
Topics: Adolescent; Adult; Carbolines; Double-Blind Method; Ejaculation; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Photic Stimulation; Piperazines; Purines; Quality of Life; Sexual Behavior; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride; Young Adult | 2011 |
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Topics: Administration, Oral; Adult; Carbolines; Dose-Response Relationship, Drug; Ejaculation; Follow-Up Studies; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Young Adult | 2011 |
A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Topics: Administration, Oral; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2012 |
Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?
Topics: Administration, Oral; Adult; Arteries; Carbolines; Humans; Impotence, Vasculogenic; Injections; Male; Middle Aged; Papaverine; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Ultrasonography, Doppler, Color; Vasodilator Agents | 2012 |
Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Topics: Adult; Aged; Carbolines; Drug Administration Schedule; Drug Substitution; Erectile Dysfunction; Europe; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Proportional Hazards Models; Prospective Studies; Purines; Recovery of Function; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2013 |
A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Topics: Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2014 |
Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction.
Topics: Adult; Carbolines; Drug Therapy, Combination; Early Medical Intervention; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Young Adult | 2015 |
PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.
Topics: Adolescent; Carbolines; Child; Exercise; Forearm; Humans; Ischemia; Male; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Spectroscopy, Near-Infrared; Sulfones; Sympathetic Nervous System; Tadalafil; Ultrasonography; Vasoconstriction | 2014 |
Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Topics: Adult; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Preference; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2015 |
Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Topics: Cardiac Surgical Procedures; Child, Preschool; Echocardiography; Female; Heart Defects, Congenital; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Infant; Iran; Length of Stay; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2017 |
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adolescent; Adult; Cardiac Catheterization; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Circulation; Pulmonary Wedge Pressure; Retrospective Studies; Sildenafil Citrate; Tadalafil; Treatment Outcome; Young Adult | 2019 |
Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
Topics: Animals; Dog Diseases; Dogs; Double-Blind Method; Electrocardiography; Female; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prospective Studies; Random Allocation; Severity of Illness Index; Sildenafil Citrate; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2019 |
[Efficacy and safety of regular use of sildenafil in the treatment of penile erectile dysfunction].
Topics: Erectile Dysfunction; Humans; Male; Penile Erection; Sildenafil Citrate; Tablets; Tadalafil; Treatment Outcome | 2019 |
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial.
Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Sildenafil Citrate; Tadalafil; Treatment Outcome; Urinary Retention | 2023 |
284 other study(ies) available for tadalafil and sildenafil citrate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; ERG1 Potassium Channel; Hypertension, Pulmonary; Microsomes, Liver; Models, Molecular; Molecular Structure; Phosphodiesterase 5 Inhibitors; Protein Conformation; Pulmonary Artery; Structure-Activity Relationship | 2018 |
Towards optimal ED management: educational forum - II.
Topics: Canada; Carbolines; Diabetes Complications; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2001 |
Phosphodiesterase inhibition: erectile dysfunction is only part of the story.
Topics: Angiotensin II; Carbolines; Cardiovascular Diseases; Delayed-Action Preparations; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2002 |
Tadalafil (Cialis) for men with erectile dysfunction.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2002 |
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Clinical Trials, Phase III as Topic; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Complications; Erectile Dysfunction; Humans; Imidazoles; Male; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2002 |
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United Kingdom; Vardenafil Dihydrochloride | 2003 |
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Binding Sites; Carbolines; Catalytic Domain; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hydrogen Bonding; Imidazoles; Models, Molecular; Phosphoric Diester Hydrolases; Piperazines; Protein Conformation; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
Topics: Carbolines; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
Cialis is here. The soft sell.
Topics: Carbolines; Commerce; Drug Industry; Erectile Dysfunction; Humans; Imidazoles; Male; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; Vardenafil Dihydrochloride | 2004 |
Pills for erectile dysfunction: now there are three.
Topics: Carbolines; Drug Interactions; Erectile Dysfunction; Food-Drug Interactions; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
Tadalafil and vardenafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Approval; Erectile Dysfunction; Forecasting; Humans; Imidazoles; Legislation, Drug; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Imidazoles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Piperazines; Purines; Pyridines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones; Tadalafil; Tenofovir; Triazines; Vardenafil Dihydrochloride | 2004 |
A consumer's guide to impotence drugs.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Enzyme Inhibitors; Erectile Dysfunction; Humans; Imidazoles; Male; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Binding Sites; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; Kinetics; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Protein Structure, Tertiary; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Tritium; Vardenafil Dihydrochloride | 2004 |
Structure elucidation of sildenafil analogues in herbal products.
Topics: Carbolines; Chromatography, Liquid; Imidazoles; Magnetic Resonance Spectroscopy; Models, Chemical; Phosphodiesterase Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cation Transport Proteins; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Heart Rate; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Potassium Channels, Voltage-Gated; Purines; Sildenafil Citrate; Sulfones; Tachycardia, Ventricular; Tadalafil; Triazines; Vardenafil Dihydrochloride; Ventricular Fibrillation | 2004 |
Development of a Micellar electrokinetic capillary chromatography method for the determination of three drugs employed in the erectile dysfunction therapy.
Topics: Carbolines; Chromatography, Micellar Electrokinetic Capillary; Erectile Dysfunction; Humans; Imidazoles; Male; Piperazines; Purines; Reproducibility of Results; Sensitivity and Specificity; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
[Birthday of a "potency pill". Helmut Newton celebrates posthumously likewise].
Topics: Carbolines; Contraceptives, Oral; Erectile Dysfunction; Erotica; Female; Germany; History, 20th Century; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Photography; Piperazines; Purines; Sexual Behavior; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adenoviridae; Adrenergic beta-Agonists; Animals; Carbolines; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fluorescence Resonance Energy Transfer; Genetic Vectors; Guanylate Cyclase; Isoproterenol; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Second Messenger Systems; Sildenafil Citrate; Soluble Guanylyl Cyclase; Sulfones; Tadalafil | 2005 |
Patient education series. Erectile dysfunction.
Topics: Carbolines; Contraindications; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphoric Diester Hydrolases; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Simultaneous determination of sildenafil, vardenafil and tadalafil as forbidden components in natural dietary supplements for male sexual potency by high-performance liquid chromatography-electrospray ionization mass spectrometry.
Topics: Carbolines; Chromatography, High Pressure Liquid; Dietary Supplements; Drug Contamination; Imidazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
ED drugs covered, but managed care unmoved.
Topics: Carbolines; Erectile Dysfunction; Formularies as Topic; Humans; Imidazoles; Insurance Coverage; Insurance, Pharmaceutical Services; Male; Managed Care Programs; Medicare; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; Vardenafil Dihydrochloride | 2005 |
Viagra, Levitra, and Cialis: what's the difference?
Topics: Adult; Age Factors; Aged; Carbolines; Contraindications; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
Viagra and anterior ischemic optic neuropathy.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Humans; Imidazoles; Male; Optic Neuropathy, Ischemic; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Brachial Artery; Capillaries; Carbolines; Fingers; Humans; Laser-Doppler Flowmetry; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Raynaud Disease; Regional Blood Flow; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Ultrasonography | 2005 |
Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Allosteric Site; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Ligands; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Protein Binding; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2005 |
Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Chromatography, High Pressure Liquid; Drug Contamination; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phytotherapy; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Aorta, Thoracic; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Endothelium, Vascular; Imidazoles; In Vitro Techniques; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation | 2006 |
Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
Topics: Adult; Carbolines; Esophageal Motility Disorders; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Evaluation, Preclinical; Gene Expression Regulation; Hypertension, Pulmonary; Hypoxia; Imidazoles; Interleukin-1; Isometric Contraction; Male; Phenylephrine; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride; Vasoconstriction | 2006 |
How new drugs help treat erectile dysfunction.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Nursing Assessment; Patient Education as Topic; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2006 |
Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Topics: Adult; Carbolines; Drug Prescriptions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Acceptance of Health Care; Phosphodiesterase Inhibitors; Piperazines; Purines; Self Administration; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2005 |
Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Clinical Trials as Topic; Erectile Dysfunction; Humans; Interpersonal Relations; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Psychometrics; Purines; Research; Self Efficacy; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome | 2005 |
Can erectile dysfunction drug use lead to ischaemic optic neuropathy?
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction.
Topics: Carbolines; Case-Control Studies; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2006 |
Beyond Viagra. What are your options?
Topics: Carbolines; Contraindications; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
Ophthalmic aspects of erectile dysfunction drugs.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adverse Drug Reaction Reporting Systems; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vision Disorders | 2006 |
Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Prescriptions; Drug Therapy, Combination; Erectile Dysfunction; Feasibility Studies; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
In that case.
Topics: Advertising; Carbolines; Confidentiality; Depression; Erectile Dysfunction; Female; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Professional-Family Relations; Purines; Sildenafil Citrate; Spouses; Sulfones; Tadalafil | 2005 |
There have been inadequate warnings that erectile dysfunction drugs can cause blindness.
Topics: Blindness; Carbolines; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Humans; Imidazoles; Incidence; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Assessment; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; Vardenafil Dihydrochloride; Vasodilator Agents; Video Recording | 2005 |
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Anemia, Sickle Cell; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Nitric Oxide; Penile Erection; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Priapism; Purines; Recurrence; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Calcium; Carbolines; Dose-Response Relationship, Drug; Imidazoles; Male; Muscle Relaxation; Muscle, Smooth; Norepinephrine; Oxadiazoles; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Quinoxalines; Rabbits; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Verapamil | 2006 |
NAION and treatment of erectile dysfunction: reply from Pfizer.
Topics: Carbolines; Case-Control Studies; Data Interpretation, Statistical; Erectile Dysfunction; Humans; Male; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices.
Topics: Benzodioxoles; Carbolines; Cyclotrons; Designer Drugs; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Imidazoles; Molecular Weight; Piperazines; Purines; Pyrimidinones; Reproducibility of Results; Sensitivity and Specificity; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Sulfones; Tadalafil; Technology, Pharmaceutical; Triazines; Vardenafil Dihydrochloride | 2006 |
Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Male; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2006 |
Regaining of morning erection and sexual confidence in patients with erectile dysfunction.
Topics: Aged; Carbolines; Circadian Rhythm; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Self Concept; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Visual loss with erectile dysfunction medications.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Atherosclerosis; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vision Disorders | 2006 |
[Effectiveness duration determines selection].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Choice Behavior; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Metabolic Clearance Rate; Middle Aged; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Treatment Outcome | 2006 |
Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
Topics: Aged; Attitude of Health Personnel; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Personal Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sexual Partners; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2006 |
A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Amino Acid Sequence; Binding Sites; Carbolines; Centrifugation, Density Gradient; Cyclic Nucleotide Phosphodiesterases, Type 5; Dimerization; Holoenzymes; Humans; Imidazoles; Inhibitory Concentration 50; Kinetics; Molecular Weight; Mutant Proteins; Phosphodiesterase Inhibitors; Piperazines; Protein Structure, Tertiary; Purines; Sildenafil Citrate; Structure-Activity Relationship; Sulfones; Tadalafil; Triazines; Tritium; Vardenafil Dihydrochloride | 2006 |
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
Detection of sildenafil analogues in herbal products for erectile dysfunction.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Molecular Structure; Phosphodiesterase Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Tadalafil associated with typical migraine aura without headache.
Topics: Atrial Fibrillation; Carbolines; Humans; Hypertension; Male; Middle Aged; Migraine with Aura; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Butylscopolammonium Bromide; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; In Vitro Techniques; Male; Middle Aged; Muscarinic Antagonists; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Nitric Oxide Donors; Nitroprusside; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Piperazines; Potassium Chloride; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Ureter; Vardenafil Dihydrochloride | 2007 |
Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Electrophoresis, Polyacrylamide Gel; Humans; Imidazoles; Ligands; Phosphodiesterase Inhibitors; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Protein Conformation; Protein Phosphatase 1; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Trypsin; Vardenafil Dihydrochloride | 2007 |
Erectile dysfunction.
Topics: Carbolines; Contraindications; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
Topics: Carbolines; Erectile Dysfunction; Female; Humans; Male; Patient Satisfaction; Personal Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sexual Partners; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome | 2007 |
[Viagra -- patients stand by their treatment].
Topics: Adult; Aged; Carbolines; Clinical Trials as Topic; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Imidazoles; In Vitro Techniques; Male; Muscle, Smooth; Nitrergic Neurons; Nitric Oxide; Penis; Phosphodiesterase Inhibitors; Piperazines; Priapism; Purines; Rabbits; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; Immunity, Innate; Male; Models, Immunological; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Prostate; Prostatitis; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Topics: Adolescent; Adult; Aged; Carbolines; Cohort Studies; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2007 |
Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
Topics: Adolescent; Adult; Aged; Carbolines; Exercise Tolerance; Female; Half-Life; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2008 |
Oral phosphodiesterase-5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Heme Oxygenase (Decyclizing); Imidazoles; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
[PDE5 inhibitors. A new option in the treatment of ureteral colic?].
Topics: Aged; Carbolines; Colic; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Isometric Contraction; Male; Middle Aged; Muscle, Smooth; Organ Culture Techniques; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Radioimmunoassay; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Ureter; Ureteral Calculi; Ureteral Diseases; Vardenafil Dihydrochloride | 2007 |
[Drug counterfeiting--the risk to the public health].
Topics: Carbolines; Drug Compounding; Drug Contamination; Drug Industry; Drug Labeling; Drug Packaging; Erectile Dysfunction; Fraud; Humans; Imidazoles; Legislation, Drug; Male; Phosphodiesterase Inhibitors; Piperazines; Poland; Public Health; Purines; Quality Control; Risk Assessment; Sildenafil Citrate; Spectrum Analysis, Raman; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
Topics: Carbolines; Erectile Dysfunction; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Patient Compliance; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Postoperative Complications; Prostate; Prostatectomy; Prostatic Neoplasms; Purines; Quality of Life; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome; Treatment Refusal; Triazines; Vardenafil Dihydrochloride | 2008 |
Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Topics: Adolescent; Adult; Aged; Carbolines; Cohort Studies; Erectile Dysfunction; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Regression Analysis; Severity of Illness Index; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2007 |
Analogues of erectile dysfunction drugs: an under-recognised threat.
Topics: Adult; Ataxia; Carbolines; Data Collection; Drug Contamination; Erectile Dysfunction; Hong Kong; Humans; Imidazoles; Male; Nonprescription Drugs; Phosphodiesterase Inhibitors; Piperazines; Plant Preparations; Purines; Pyrimidinones; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
[Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].
Topics: Biopsy; Carbolines; Erectile Dysfunction; Humans; Male; Nervous System Diseases; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; United States; United States Food and Drug Administration | 2007 |
Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Topics: 1-Methyl-3-isobutylxanthine; Amino Acid Sequence; Animals; Binding Sites; Carbolines; Catalytic Domain; Crystallography, X-Ray; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Histidine; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Kinetics; Molecular Sequence Data; Mutation; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sequence Alignment; Sildenafil Citrate; Sulfones; Tadalafil; Thermodynamics; Triazines; Tyrosine; Vardenafil Dihydrochloride | 2007 |
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
Topics: Adult; Aged; Carbolines; Erectile Dysfunction; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2008 |
The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Heme Oxygenase (Decyclizing); Imidazoles; Male; Penis; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2008 |
Erectile dysfunction: the Viagra revolution.
Topics: Carbolines; Ejaculation; Erectile Dysfunction; Humans; Imidazoles; Male; Nitric Oxide; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Topics: Aged; Benzamides; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; In Vitro Techniques; Male; Middle Aged; Norepinephrine; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostate; Purines; Pyridines; Rolipram; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
Topics: Animals; Blood Platelets; Calcium; Calcium Channel Blockers; Calcium Channels; Carbolines; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Imidazoles; In Vitro Techniques; Male; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rabbits; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation | 2008 |
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quantitative Structure-Activity Relationship; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Can Viagra really cause hearing and vision loss? If so, is this a reason to avoid using it?
Topics: Carbolines; Hearing Loss; Humans; Imidazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride; Vision Disorders | 2008 |
Structural elucidation of a tadalafil analogue found in a dietary supplement.
Topics: Carbolines; Chromatography, Thin Layer; Dietary Supplements; Magnetic Resonance Spectroscopy; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2008 |
Use of phosphodiesterase-5 inhibitors by college students.
Topics: Adolescent; Adult; Brazil; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Self Medication; Sildenafil Citrate; Students; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Young Adult | 2008 |
Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Topics: Animals; Carbolines; Drug Evaluation, Preclinical; Enzyme Inhibitors; Guanylate Cyclase; Imidazoles; Male; Muscle Contraction; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Nitroglycerin; Oxadiazoles; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quinoxalines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2009 |
Management of erectile dysfunction in general practice.
Topics: Attitude of Health Personnel; Carbolines; Cardiovascular Diseases; Drug Prescriptions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Physician-Patient Relations; Piperazines; Practice Patterns, Physicians'; Primary Health Care; Purines; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Detection of undeclared erectile dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry.
Topics: Adult; Amines; Carbolines; Dietary Supplements; Drug Contamination; Erectile Dysfunction; Humans; Imidazoles; Ions; Male; Piperazines; Plant Preparations; Purines; Reference Standards; Sildenafil Citrate; Spectrum Analysis; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Time Factors; Triazines; Vardenafil Dihydrochloride | 2009 |
An unusual outbreak of hypoglycemia.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Chromatography, High Pressure Liquid; Disease Outbreaks; Drug Contamination; Erectile Dysfunction; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Illicit Drugs; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Plant Extracts; Purines; Sildenafil Citrate; Singapore; Sulfones; Tadalafil; Young Adult | 2009 |
Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Topics: Adolescent; Adult; Aged; Carbolines; Humans; Imidazoles; Male; Middle Aged; Muscle Relaxation; Nitric Oxide; Penis; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Young Adult | 2009 |
Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatectomy; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2009 |
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Topics: Age Distribution; Aged; Audiometry; Carbolines; Cohort Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Follow-Up Studies; Hearing Loss, Sudden; Hearing Tests; Humans; Incidence; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sildenafil Citrate; Sulfones; Tadalafil | 2009 |
High performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of vardenafil, sildenafil, tadalafil, testosterone and local anesthetics in cosmetic creams sold on the Internet web sites.
Topics: Anesthetics, Local; Carbolines; Chromatography, High Pressure Liquid; Cosmetics; Female; Humans; Imidazoles; Internet; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Testosterone; Triazines; Vardenafil Dihydrochloride | 2009 |
Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildenafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC-MS/TOF.
Topics: Aphrodisiacs; Carbolines; Chromatography, Liquid; Drug Contamination; Humans; Imidazoles; India; Male; Mass Spectrometry; Medicine, Ayurvedic; Phosphodiesterase Inhibitors; Piperazines; Plant Preparations; Purines; Reference Standards; Reproducibility of Results; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
Topics: Allosteric Regulation; Allosteric Site; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Electrophoresis, Gel, Two-Dimensional; Humans; Ligands; Magnesium; Phosphodiesterase 5 Inhibitors; Piperazines; Point Mutation; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2009 |
Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
Topics: Analysis of Variance; Animals; Area Under Curve; Arousal; Brain; Carbolines; Cyclic GMP; Dopamine; Female; Imidazoles; Male; Microdialysis; Muscle, Smooth; Nitric Oxide; Nucleus Accumbens; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Ventral Tegmental Area | 2009 |
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Practice Patterns, Physicians'; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
Topics: Carbolines; Clitoris; Education, Medical, Continuing; Female; Hearing Disorders; Humans; Imidazoles; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sexual Dysfunctions, Psychological; Sexuality; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Postoperative Complications; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Purines; Robotics; Sildenafil Citrate; Sulfones; Tadalafil; Trauma, Nervous System; Treatment Outcome | 2010 |
The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis and the optical purity of tadalafil stereoisomers.
Topics: Carbolines; Drug Contamination; Fraud; Optical Rotation; Piperazines; Purines; Sildenafil Citrate; Spectroscopy, Near-Infrared; Stereoisomerism; Sulfones; Tadalafil | 2010 |
Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model.
Topics: Animals; Carbolines; Climacteric; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Flushing; Gene Expression Regulation; Imidazoles; Male; Mice; Mice, Inbred ICR; Models, Animal; Nitrates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; RNA, Messenger; Sex Characteristics; Sildenafil Citrate; Skin; Sulfones; Tadalafil; Tail; Triazines; Vardenafil Dihydrochloride | 2009 |
Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column.
Topics: Carbolines; Food Analysis; Gas Chromatography-Mass Spectrometry; Imidazoles; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Topics: Animals; Blood Gas Analysis; Carbolines; Cyclic GMP; Disease Progression; Dose-Response Relationship, Drug; Hemodynamics; Hydrogen-Ion Concentration; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Organ Size; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Poisons; Pulmonary Circulation; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Survival; Tadalafil | 2009 |
Phosphodiesterase type V inhibitors: Occurrence and fate in wastewater and sewage sludge.
Topics: Carbolines; Chromatography, Liquid; Germany; Imidazoles; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Reproducibility of Results; Sewage; Sildenafil Citrate; Spain; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification | 2010 |
Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study.
Topics: Adolescent; Adult; Carbolines; Case-Control Studies; Central Serous Chorioretinopathy; Databases, Factual; Drug Prescriptions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Product Surveillance, Postmarketing; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; United States Department of Veterans Affairs; Vardenafil Dihydrochloride; Young Adult | 2010 |
Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Triazines; Vardenafil Dihydrochloride | 2009 |
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
Topics: Azotemia; Blood Pressure; Carbolines; Diuresis; Diuretics; Edema; Glomerular Filtration Rate; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Heart Disease; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
Effects of sildenafil and tadalafil on intraocular pressure in sheep: implications for aqueous humor dynamics.
Topics: Administration, Oral; Animals; Aqueous Humor; Carbolines; Female; Intraocular Pressure; Male; Piperazines; Purines; Sheep; Sildenafil Citrate; Sulfones; Tadalafil; Tonometry, Ocular; Vasodilator Agents | 2010 |
Erectile dysfunction.
Topics: Blood Glucose; Carbolines; Cardiovascular Diseases; Cholesterol; Erectile Dysfunction; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
[Therapy of erectile dysfunction].
Topics: Adrenergic alpha-Antagonists; Androgens; Carbolines; Diagnosis, Differential; Erectile Dysfunction; Humans; Imidazoles; Injections; Male; Penile Implantation; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vacuum; Vardenafil Dihydrochloride; Vasodilator Agents | 2010 |
Phosphodiesterase inhibitors for pulmonary hypertension.
Topics: Carbolines; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Meta-Analysis as Topic; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
Development of acute lympboblastic leukemia in a patient with increased hematogones after toxic bone marrow damage.
Topics: Adult; B-Lymphocytes; Bone Marrow Diseases; Carbolines; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
Identification of counterfeit medicines for erectile dysfunction from an illegal supply chain.
Topics: Carbolines; Chromatography, High Pressure Liquid; Croatia; Erectile Dysfunction; Fraud; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
Recreational use of erectile dysfunction medications in undergraduate men in the United States: characteristics and associated risk factors.
Topics: Adolescent; Adult; Carbolines; Chi-Square Distribution; Cross-Sectional Studies; Humans; Imidazoles; Male; Piperazines; Purines; Risk Factors; Risk-Taking; Sexual Behavior; Sexuality; Sildenafil Citrate; Students; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Evaluation of therapeutic response of patients with erectile dysfunction.
Topics: Adolescent; Adult; Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Patient Preference; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Young Adult | 2009 |
Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Topics: Adolescent; Adult; Aged; Carbolines; Databases, Factual; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Nitrates; Pharmaceutical Services; Phosphodiesterase Inhibitors; Piperazines; Practice Patterns, Physicians'; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Young Adult | 2010 |
A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine.
Topics: Carbolines; Gas Chromatography-Mass Spectrometry; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Topics: Carbolines; Diagnosis, Differential; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Patient Care Team; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Referral and Consultation; Risk Factors; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2010 |
Simultaneous determination of yohimbine, sildenafil, vardenafil and tadalafil in dietary supplements using high-performance liquid chromatography-tandem mass spectrometry.
Topics: Adrenergic alpha-Antagonists; Carbolines; Chromatography, High Pressure Liquid; Dietary Supplements; Erectile Dysfunction; Humans; Imidazoles; Male; Molecular Structure; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride; Yohimbine | 2010 |
Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain.
Topics: Animals; Brain; Carbolines; Female; Fetus; Glutathione Peroxidase; Malondialdehyde; Piperazines; Pregnancy; Purines; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Sildenafil Citrate; Sulfones; Superoxide Dismutase; Tadalafil; Vasodilator Agents | 2011 |
Comparison and combination of spectroscopic techniques for the detection of counterfeit medicines.
Topics: Carbolines; Least-Squares Analysis; Phosphodiesterase Inhibitors; Piperazines; Principal Component Analysis; Purines; Sildenafil Citrate; Spectroscopy, Fourier Transform Infrared; Spectroscopy, Near-Infrared; Spectrum Analysis, Raman; Sulfones; Tadalafil | 2010 |
Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Atropine; Behavior, Animal; Carbolines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Swimming; Tadalafil | 2010 |
Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.
Topics: Acetazolamide; Acute Disease; Albuterol; Altitude Sickness; Brain Edema; Carbolines; Dexamethasone; Humans; Mountaineering; Nifedipine; Piperazines; Pulmonary Edema; Purines; Salmeterol Xinafoate; Sildenafil Citrate; Societies; Sulfones; Tadalafil; Wilderness Medicine | 2010 |
[Benefits of tadalafil in sexual activity-related time concerns].
Topics: Carbolines; Erectile Dysfunction; Female; Humans; Imidazoles; Interpersonal Relations; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Time Factors; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2010 |
Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
Topics: Carbolines; Counterfeit Drugs; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Time Factors | 2010 |
[Dietary supplements on the domestic market adulterated with sildenafil and tadalafil].
Topics: Aphrodisiacs; Carbolines; Dietary Supplements; Drug Contamination; Erectile Dysfunction; Humans; Hungary; Male; Phosphodiesterase Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
Separation and structural elucidation of a novel analogue of vardenafil included as an adulterant in a dietary supplement by liquid chromatography-electrospray ionization mass spectrometry, infrared spectroscopy and nuclear magnetic resonance spectroscopy
Topics: Carbolines; Chromatography, Liquid; Dietary Supplements; Drug Contamination; Erectile Dysfunction; Humans; Imidazoles; Magnetic Resonance Spectroscopy; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Saccharomyces cerevisiae; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
The impact of oral ED medication on female partners' relationship satisfaction.
Topics: Adult; Aged; Carbolines; Communication; Emotions; Erectile Dysfunction; Female; Humans; Interpersonal Relations; Interviews as Topic; Male; Middle Aged; Personal Satisfaction; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2011 |
Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro.
Topics: Adipocytes; Aromatase; Blotting, Western; Carbolines; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Humans; In Vitro Techniques; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reverse Transcriptase Polymerase Chain Reaction; Sildenafil Citrate; Sulfones; Tadalafil | 2011 |
Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study.
Topics: Animals; Apoptosis; Carbolines; Ceftriaxone; Imidazoles; Kidney Tubules; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Ureteral Obstruction; Vardenafil Dihydrochloride | 2011 |
Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Topics: Allosteric Regulation; Allosteric Site; Animals; Carbolines; Carrier Proteins; Catalytic Domain; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Phosphodiesterase 5 Inhibitors; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Purines; Sildenafil Citrate; Substrate Specificity; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Impurity fingerprints for the identification of counterfeit medicines--a feasibility study.
Topics: Algorithms; Carbolines; Chromatography, High Pressure Liquid; Counterfeit Drugs; Discriminant Analysis; Drug Contamination; Feasibility Studies; Least-Squares Analysis; Piperazines; Principal Component Analysis; Purines; Sildenafil Citrate; Spectrophotometry, Ultraviolet; Sulfones; Tablets; Tadalafil | 2011 |
Identification of novel sildenafil-analogues in an adulterated herbal food supplement.
Topics: Carbolines; Dietary Supplements; Drug Contamination; Food Contamination; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry.
Topics: Brazil; Carbolines; Chemistry, Pharmaceutical; Counterfeit Drugs; Multivariate Analysis; Phosphodiesterase 5 Inhibitors; Piperazines; Principal Component Analysis; Public Health; Purines; Sildenafil Citrate; Spectrometry, X-Ray Emission; Sulfones; Tablets; Tadalafil | 2012 |
10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Topics: Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Product Surveillance, Postmarketing; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2012 |
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Topics: Animals; Blood Pressure; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Gene Expression Regulation, Enzymologic; In Vitro Techniques; Male; Middle Cerebral Artery; Morpholines; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2012 |
Recurrent ischemic stroke associated with sildenafil and tadalafil use in a young adult.
Topics: Brain; Brain Ischemia; Carbolines; Coitus; Headache; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Paresis; Piperazines; Purines; Recurrence; Sildenafil Citrate; Smoking; Stroke; Sulfones; Tadalafil; Vasodilator Agents | 2012 |
How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Carbolines; Disease Models, Animal; Drug Administration Schedule; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Inbred Strains; Sildenafil Citrate; Sulfones; Tadalafil | 2012 |
Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
Topics: Adolescent; Carbolines; Cardiac Output; Child; Child, Preschool; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Statistics, Nonparametric; Sulfones; Tadalafil; Treatment Outcome; Vascular Resistance | 2012 |
Phosphodiesterase 5 inhibitors in vascular systemic disorders.
Topics: Animals; Carbolines; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vascular Diseases; Vasodilator Agents | 2012 |
Effect of testosterone and frequent low-dose sildenafil/tadalafil on cavernous tissue oxidative stress of aged diabetic rats.
Topics: Aging; Animals; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Erectile Dysfunction; Glutathione Peroxidase; Male; Malondialdehyde; Oxidative Stress; Penile Erection; Penis; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone; Vasodilator Agents | 2012 |
PDEI-5 for erectile dysfunction: a potential role in seizure susceptibility.
Topics: Aged; Animals; Carbolines; Disease Susceptibility; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prevalence; Purines; Rats; Seizures; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2012 |
Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples.
Topics: Acetonitriles; Animals; Biotransformation; Brain; Calibration; Carbolines; Chromatography, Liquid; Dealkylation; Formates; Imidazoles; Injections, Intraperitoneal; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2012 |
Screening for multiple phosphodiesterase type 5 inhibitor drugs in dietary supplement materials by flow injection mass spectrometry and their quantification by liquid chromatography tandem mass spectrometry.
Topics: Carbolines; Chromatography, Liquid; Dietary Supplements; Drug Contamination; Flow Injection Analysis; Imidazoles; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Piperazines; Plant Preparations; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2012 |
Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Topics: Animals; Carbolines; Dogs; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Imidazoles; Infusions, Intravenous; Male; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2012 |
The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.
Topics: Animals; Apoptosis; Carbolines; Gene Expression; Ischemia; Kidney; Male; Malondialdehyde; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Peroxidase; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sildenafil Citrate; Sulfones; Tadalafil; Tumor Suppressor Protein p53 | 2012 |
Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Topics: Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2012 |
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbolines; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Half-Life; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Species Specificity; Sulfones; Tadalafil; Tissue Distribution | 2013 |
Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
Topics: Adult; Aged; Carbolines; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents; Young Adult | 2012 |
The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
Topics: Adult; Aged; Carbolines; Comorbidity; Coronary Artery Disease; Cross-Sectional Studies; Drug Administration Schedule; Drug Utilization; Erectile Dysfunction; Health Surveys; Humans; Illicit Drugs; Imidazoles; Internet; Male; Middle Aged; Nonprescription Drugs; Phosphodiesterase Inhibitors; Piperazines; Prescription Drugs; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; Vardenafil Dihydrochloride | 2013 |
Viagra and Cialis for heart failure? Erectile dysfunction drugs may do what no others have done.
Topics: Autonomic Nervous System; Carbolines; Cardiovascular Agents; Heart Rate; Humans; Myocardial Infarction; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2012 |
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Topics: Adult; Aged; Antihypertensive Agents; Biotransformation; Carbolines; Chromatography, High Pressure Liquid; Drug Monitoring; Familial Primary Pulmonary Hypertension; Forensic Toxicology; Humans; Hypertension, Pulmonary; Imidazoles; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2012 |
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Topics: Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Bosentan; Carbolines; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Endothelin A Receptor Antagonists; Gene Expression Regulation; Genes, Reporter; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Peroxisome-Targeting Signal 1 Receptor; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pregnane X Receptor; Promoter Regions, Genetic; Purines; Pyridazines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Proteins; RNA, Messenger; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil | 2013 |
Rapid-screening detection of acetildenafils, sildenafils and avanafil by ion mobility spectrometry.
Topics: Carbolines; Chemistry Techniques, Analytical; Dietary Supplements; Food Contamination; Food Inspection; Imidazoles; Isomerism; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2013 |
Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.
Topics: Adult; Aged; Animals; Benzimidazoles; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Erectile Dysfunction; Humans; Male; Middle Aged; Nitric Oxide; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Potassium Channels, Calcium-Activated; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilation; Vasodilator Agents | 2013 |
Prescription opioids for back pain and use of medications for erectile dysfunction.
Topics: Adult; Age Factors; Aged; Analgesics, Opioid; Androgens; Back Pain; Carbolines; Comorbidity; Cross-Sectional Studies; Depression; Drug Prescriptions; Erectile Dysfunction; Hormone Replacement Therapy; Humans; Imidazoles; Insurance, Health; Logistic Models; Male; Middle Aged; Piperazines; Prevalence; Purines; Sildenafil Citrate; Smoking; Sulfones; Tadalafil; Testosterone; Triazines; United States; Urological Agents; Vardenafil Dihydrochloride | 2013 |
[Non-arteritic anterior ischemic optic neuropathy associated with erectile dysfunction medications].
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Topics: Carbolines; Carbonates; Erectile Dysfunction; Humans; Imidazoles; Latin America; Male; Medication Adherence; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Purines; Pyrimidines; Self Concept; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2013 |
A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
Topics: Carbolines; Egypt; Erectile Dysfunction; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Purines; Saudi Arabia; Self Concept; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Treatment Outcome; Triazines; United Arab Emirates; Vardenafil Dihydrochloride | 2013 |
[Intracavernous injection: a treatment modality for erectile dysfunction].
Topics: Alprostadil; Carbolines; Erectile Dysfunction; Humans; Injections; Male; Middle Aged; Penis; Piperazines; Purines; Self Administration; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2013 |
Effect of acute tadalafil on sperm motility and acrosome reaction: in vitro and in vivo studies.
Topics: Acrosome Reaction; Adult; Asthenozoospermia; Carbolines; Humans; In Vitro Techniques; Male; Piperazines; Purines; Semen Analysis; Sildenafil Citrate; Sperm Motility; Sulfones; Tadalafil | 2014 |
Condom attitudes of heterosexual men ages 50 and older using prescribed drugs (Viagra, Cialis, Levitra) to treat erectile dysfunction.
Topics: Carbolines; Condoms; Erectile Dysfunction; Female; Health Behavior; Health Promotion; Heterosexuality; Humans; Imidazoles; Male; Middle Aged; Piperazines; Purines; Safe Sex; Sexual Partners; Sexually Transmitted Diseases; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2013 |
Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors.
Topics: Carbolines; Chromatography, Liquid; Dietary Supplements; Drug Labeling; Erectile Dysfunction; Humans; Male; Mass Spectrometry; Nonprescription Drugs; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; United States | 2013 |
[Oral tadalafil on alternate days for erectile dysfunction that fails to respond to on-demand sildenafil: a report of 15 cases].
Topics: Administration, Oral; Adult; Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Treatment Outcome | 2013 |
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Carbolines; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclin D1; HCT116 Cells; HT29 Cells; Humans; Inhibitor of Apoptosis Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Sulindac; Survivin; Tadalafil; Wnt Signaling Pathway | 2013 |
Sildenafil and tadalafil in simulated chlorination conditions: ecotoxicity of drugs and their derivatives.
Topics: Animals; Aquatic Organisms; Carbolines; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cladocera; Halogenation; Hydrocarbons, Chlorinated; Magnetic Resonance Spectroscopy; Mutagenicity Tests; Piperazines; Purines; Rotifera; Sildenafil Citrate; Sulfones; Tadalafil; Toxicity Tests; Wastewater; Water Pollutants, Chemical | 2013 |
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Assisted semen collection using two phosphodiesterase type 5 inhibitors (Tadalafil and Sildenafil) in infertile men with mild erectile dysfunction.
Topics: Adult; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Semen; Sildenafil Citrate; Specimen Handling; Sulfones; Tadalafil | 2013 |
Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.
Topics: Analysis of Variance; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Organ Size; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Simvastatin; Sulfones; Tadalafil; Urinary Bladder; Urinary Bladder, Neurogenic; Urine | 2013 |
Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples.
Topics: Carbolines; Chromatography, Liquid; Forensic Toxicology; Humans; Imidazoles; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2013 |
The selectivity and potency of the new PDE5 inhibitor TPN729MA.
Topics: Animals; Blood Pressure; Carbolines; Dogs; Erectile Dysfunction; Humans; Inhibitory Concentration 50; Isoenzymes; Male; Nitroprusside; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Monitoring by LC-MS/MS of 48 compounds of sildenafil, tadalafil, vardenafil and their analogues in illicit health food products in the Korean market advertised as enhancing male sexual performance.
Topics: Advertising; Carbolines; Chromatography, Liquid; Food Contamination; Food, Organic; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reproductive Health; Republic of Korea; Sildenafil Citrate; Substance Abuse Detection; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2013 |
The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Topics: Binding Sites; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 6; Erectile Dysfunction; Humans; Imidazoles; Ligands; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Purines; Sildenafil Citrate; Structural Homology, Protein; Sulfones; Tadalafil; Thermodynamics; Triazines; Urological Agents; Vardenafil Dihydrochloride | 2013 |
Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Carbolines; Child; Child, Preschool; Dose-Response Relationship, Drug; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Wedge Pressure; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Walking; Young Adult | 2014 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Carbolines; Drug Costs; Erectile Dysfunction; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Compliance; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; State Medicine; Sulfones; Tadalafil; Triazines; United Kingdom; Vardenafil Dihydrochloride; Young Adult | 2014 |
Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.
Topics: Age Factors; Aged; Carbolines; Humans; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Piperazines; Prescription Drugs; Purines; Risk; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone | 2014 |
Simultaneous identification of 18 illegal adulterants in dietary supplements by using high-performance liquid chromatography-mass spectrometry.
Topics: Acetonitriles; Benzodioxoles; Carbolines; Chromatography, High Pressure Liquid; Dietary Supplements; Food Contamination; Formates; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Quality Control; Sildenafil Citrate; Solutions; Sulfones; Tadalafil; Urological Agents; Vasodilator Agents | 2014 |
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Topics: Aged; Aged, 80 and over; Carbolines; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Purines; Respiratory Function Tests; Sildenafil Citrate; Sulfonamides; Tadalafil; Walking | 2014 |
Headspace-gas chromatographic fingerprints to discriminate and classify counterfeit medicines.
Topics: Carbolines; Counterfeit Drugs; Drug Contamination; Gas Chromatography-Mass Spectrometry; Piperazines; Principal Component Analysis; Purines; Reproducibility of Results; Risk Factors; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Substitution; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome; United States; Vasodilator Agents; Young Adult | 2014 |
Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon.
Topics: Administration, Oral; Adult; Aged; Carbolines; Female; Fingers; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Prospective Studies; Purines; Raynaud Disease; Regional Blood Flow; Sildenafil Citrate; Skin Temperature; Sulfonamides; Sulfones; Tadalafil; Thermography; Time Factors; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2014 |
Effects of the recreational use of PDE5 inhibitors on the corpus cavernosum of young, healthy rats.
Topics: Animals; Carbolines; Collagen; Fibroblasts; Imidazoles; Male; Microscopy, Electron; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2014 |
Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Topics: Arteries; Benzopyrans; Carbolines; Cyclic GMP; Diabetes Mellitus, Type 2; Drug Synergism; Erectile Dysfunction; Ethanolamines; Humans; Imidazoles; Male; Middle Aged; Muscle Relaxation; Muscle, Smooth, Vascular; Nebivolol; Nitric Oxide; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Life Style; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2014 |
Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.
Topics: Carbolines; DNA-Binding Proteins; Drug Synergism; Endoplasmic Reticulum Stress; Endoribonucleases; Glioblastoma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Serine-Threonine Kinases; Purines; Pyrazoles; Regulatory Factor X Transcription Factors; Sildenafil Citrate; Sulfonamides; Tadalafil; Transcription Factors; Transfection; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2014 |
Chromatographic analysis of some drugs employed in erectile dysfunction therapy: qualitative and quantitative studies using calixarene stationary phase.
Topics: Apomorphine; Buffers; Calixarenes; Carbolines; Chromatography, High Pressure Liquid; Erectile Dysfunction; Humans; Hydrogen-Ion Concentration; Limit of Detection; Male; Pharmaceutical Preparations; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Effect of avanafil on rat and human corpus cavernosum.
Topics: Animals; Blood Pressure; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Male; Penis; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Tadalafil; Vasodilation | 2015 |
Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Topics: Adult; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Risk Assessment; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2015 |
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Topics: Aged; Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Substitution; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2015 |
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease.
Topics: Animals; Bacteria; Carbolines; Cell Death; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation; Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrazoles; Sildenafil Citrate; Sulfonamides; Tadalafil; Viruses | 2015 |
Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Arterial Pressure; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Iran; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sildenafil Citrate; Tadalafil | 2016 |
Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation.
Topics: Animals; Binding Sites; Cell Line; Cytochrome P-450 CYP3A; Dealkylation; Humans; Insecta; Isoenzymes; Microsomes; Models, Molecular; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2015 |
PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Proto-Oncogene Proteins B-raf; Sildenafil Citrate; Tadalafil; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2015 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Topics: Drug Prescriptions; Erectile Dysfunction; Home Care Services; Housing for the Elderly; Humans; Male; Phosphodiesterase 5 Inhibitors; Retrospective Studies; Sildenafil Citrate; Tadalafil | 2015 |
Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats.
Topics: Animals; Biopsy, Needle; Blood Flow Velocity; Disease Models, Animal; Female; Graft Rejection; Immunohistochemistry; Infusions, Intravenous; Laser-Doppler Flowmetry; Microcirculation; Random Allocation; Rats; Rats, Wistar; Reference Values; Sildenafil Citrate; Skin Transplantation; Surgical Flaps; Tadalafil; Vardenafil Dihydrochloride; Wound Healing | 2015 |
Male enhancement Nutraceuticals in the Middle East market: Claim, pharmaceutical quality and safety assessments.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Creatinine; Dietary Supplements; Drug Contamination; gamma-Glutamyltransferase; Male; Middle East; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Sildenafil Citrate; Tadalafil; Urea; Vardenafil Dihydrochloride | 2015 |
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity | 2015 |
Positive effect of tadalafil, a phosphodiesterase-5 inhibitor, on fracture healing in rat femur.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Femoral Fractures; Fracture Healing; Male; Phosphodiesterase 5 Inhibitors; Radiography; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2015 |
A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
Topics: Aged; Cranial Nerve Diseases; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2015 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
Topics: Administration, Oral; Cost-Benefit Analysis; Humans; Hypertension, Pulmonary; Markov Chains; Quality-Adjusted Life Years; Sildenafil Citrate; Tadalafil | 2016 |
[Rapid screening and confirmation of illegally added anti- impotence preparations in health care products by high performance liquid chromatography-high resolution mass spectrometry].
Topics: Benzylamines; Chromatography, High Pressure Liquid; Drug Contamination; Erectile Dysfunction; Humans; Indole Alkaloids; Male; Mass Spectrometry; Naphthalenes; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; Vasodilator Agents | 2015 |
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Topics: Adult; Aged; Female; Heterotrimeric GTP-Binding Proteins; Humans; Hypertension, Pulmonary; INDEL Mutation; Male; Middle Aged; Peptidyl-Dipeptidase A; Phosphodiesterase 5 Inhibitors; Polymorphism, Genetic; Retrospective Studies; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2016 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Simultaneous Determination of Sildenafil and Tadalafil in Legal Drugs, Illicit/Counterfeit Drugs, and Wastewater Samples by High-Performance Liquid Chromatography.
Topics: Chromatography, High Pressure Liquid; Counterfeit Drugs; Illicit Drugs; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vasodilator Agents; Wastewater | 2016 |
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Topics: Animals; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Erectile Dysfunction; Isoenzymes; Liver; Male; Metabolic Detoxication, Phase I; Phosphodiesterase 5 Inhibitors; Rats; Risk Assessment; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2016 |
Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
Topics: Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Phosphodiesterase 5 Inhibitors; Product Surveillance, Postmarketing; Pyrimidines; Retinal Artery Occlusion; Retinal Vein Occlusion; Sildenafil Citrate; Tadalafil; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2016 |
Prevalence of use of erectile dysfunction medication by Dutch military personnel between 2003 and 2012.
Topics: Adult; Clinical Pharmacy Information Systems; Erectile Dysfunction; Humans; Male; Military Personnel; Netherlands; Psychotropic Drugs; Risk Factors; Sildenafil Citrate; Surveys and Questionnaires; Tadalafil | 2017 |
A genetic algorithm-based framework for wavelength selection on sample categorization.
Topics: Algorithms; Anesthetics, Local; Cocaine; Counterfeit Drugs; Illicit Drugs; Sildenafil Citrate; Spectroscopy, Fourier Transform Infrared; Tadalafil; Vasodilator Agents | 2017 |
Determination of Common Adulterants in Herbal Medicine and Food Samples using Core-shell Column Coupled to Tandem Mass Spectrometry.
Topics: Chromatography, Liquid; Drug Contamination; Food Analysis; Food Contamination; Household Products; Oman; Plant Preparations; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2017 |
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
ATR-FTIR characterization of generic brand-named and counterfeit sildenafil- and tadalafil-based tablets found on the Brazilian market.
Topics: Brazil; Counterfeit Drugs; Drugs, Generic; Humans; Sildenafil Citrate; Spectroscopy, Fourier Transform Infrared; Tadalafil | 2017 |
Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
Topics: Blood Platelets; Chromatography, Liquid; Cyclic GMP; Humans; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry | 2017 |
The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension.
Topics: Cyclic GMP; Drug Therapy, Combination; Endothelins; Enzyme Activators; Humans; Hypertension, Pulmonary; Molecular Targeted Therapy; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Precision Medicine; Pyrazoles; Pyrimidines; Signal Transduction; Sildenafil Citrate; Tadalafil | 2017 |
[Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
Topics: Central Serous Chorioretinopathy; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tomography, Optical Coherence | 2017 |
Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression.
Topics: Adiponectin; Animals; Anti-Arrhythmia Agents; Apoptosis; Arrhythmias, Cardiac; Caspase 3; Creatine Kinase; Disease Models, Animal; Electrocardiography; Epinephrine; Glutathione; Heart Rate; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocardium; Necrosis; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2018 |
Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Topics: Animals; Benzoates; Cyclic GMP; Disease Models, Animal; Enzyme Activators; Female; Ischemic Postconditioning; Large-Conductance Calcium-Activated Potassium Channels; Male; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Tetrazoles; Thiourea; Time Factors; Up-Regulation | 2018 |
Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries.
Topics: Adult; Aged; Brazil; China; Coitus; Drug Administration Schedule; Erectile Dysfunction; Habits; Humans; Italy; Japan; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Russia; Sildenafil Citrate; Surveys and Questionnaires; Tadalafil; Taiwan; Time Factors; Turkey; Vardenafil Dihydrochloride | 2018 |
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Topics: Aged; Aged, 80 and over; Chronic Disease; Drug Substitution; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Tadalafil | 2018 |
Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
Topics: Bacterial Proteins; Binding Sites; Drug Repositioning; Escherichia coli; Hydroquinones; Microbial Sensitivity Tests; Models, Molecular; Molecular Docking Simulation; Mycobacterium tuberculosis; Protein Binding; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2018 |
Evaluation of Sildenafil and Tadalafil for Reversing Constriction of Fetal Arteries in a Human Placenta Perfusion Model.
Topics: Arteries; Female; Fetal Growth Retardation; Humans; Perfusion; Phosphodiesterase 5 Inhibitors; Placenta; Pregnancy; Sildenafil Citrate; Tadalafil; Vasoconstriction | 2018 |
Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?
Topics: Angioplasty, Balloon; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Therapy, Combination; Endarterectomy; Epoprostenol; Genome-Wide Association Study; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Molecular Targeted Therapy; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Embolism; Pyridazines; Randomized Controlled Trials as Topic; Registries; Sildenafil Citrate; Tadalafil | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Interval importance index to select relevant ATR-FTIR wavenumber Intervals for falsified drug classification.
Topics: Brazil; Counterfeit Drugs; Erectile Dysfunction; Fraud; Humans; Male; Models, Chemical; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Spectroscopy, Fourier Transform Infrared; Statistics, Nonparametric; Tadalafil; Urological Agents | 2018 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
Association of Transient Colorblindness With Sildenafil and Tadalafil.
Topics: Color Perception Tests; Color Vision; Color Vision Defects; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2019 |
Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions.
Topics: Chromatography, Liquid; Erectile Dysfunction; Humans; Illicit Drugs; Male; Pyrimidines; Sildenafil Citrate; Stomach; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2019 |
Sildenafil Use in Children with Pulmonary Hypertension.
Topics: Adolescent; Bronchopulmonary Dysplasia; Child; Child, Preschool; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Comparison between counterfeit and authentic medicines: A novel approach using differential scanning calorimetry and hierarchical cluster analysis.
Topics: Brazil; Calorimetry, Differential Scanning; Cluster Analysis; Counterfeit Drugs; Erectile Dysfunction; Excipients; Humans; Male; Phosphodiesterase 5 Inhibitors; Principal Component Analysis; Sildenafil Citrate; Tadalafil | 2019 |
A hierarchical screening method for detection of illegal adulterants in Fur seal ginseng pills by profiling analysis of HPLC multi-dimensional fingerprints.
Topics: Chromatography, High Pressure Liquid; Drug Contamination; Functional Food; Panax; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tablets; Tadalafil | 2019 |
Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Female; Glutathione; Inflammation; Lung; Male; Malondialdehyde; Nitric Oxide; Nitrosative Stress; Oxidative Stress; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil | 2019 |
Enhancing counterfeit and illicit medicines grouping via feature selection and X-ray fluorescence spectrometry.
Topics: Cluster Analysis; Counterfeit Drugs; Multivariate Analysis; Phosphodiesterase 5 Inhibitors; Principal Component Analysis; Sildenafil Citrate; Spectrometry, X-Ray Emission; Tablets; Tadalafil | 2019 |
Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials.
Topics: Adolescent; Child; Direct-to-Consumer Advertising; Drug Industry; Erectile Dysfunction; Guideline Adherence; Guidelines as Topic; Humans; Male; Prescription Drugs; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; Vasodilator Agents | 2019 |
Development of a specific fragment pattern-based quadrupole-Orbitrap mass spectrometry method to screen adulterated products of phosphodiesterase-5 inhibitors and their analogues.
Topics: Chromatography, High Pressure Liquid; Counterfeit Drugs; Dietary Supplements; Drug Contamination; Food Contamination; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; Vasodilator Agents | 2019 |
Falsified vardenafil tablets available online.
Topics: Counterfeit Drugs; Humans; Japan; Pharmaceutical Services, Online; Principal Component Analysis; Quality Control; Sildenafil Citrate; Spectrum Analysis, Raman; Tablets; Tadalafil; Urological Agents; Vardenafil Dihydrochloride | 2020 |
The prevalence of gamma-hydroxybutyrate (GHB) in motor vehicle drivers and its co-administration with amphetamine type substances (ATS) in Queensland, Australia (2011-2018).
Topics: Adult; Amphetamines; Australia; Benzodiazepines; Driving Under the Influence; Female; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Narcotics; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sodium Oxybate; Substance Abuse Detection; Substance-Related Disorders; Tadalafil | 2019 |
Comparison of the protective effects of sildenafil, vardenafil and tadalafil treatments in ischemia-reperfusion injury in rat ovary.
Topics: Animals; Female; Ovarian Diseases; Ovary; Protective Agents; Rats; Rats, Wistar; Reperfusion Injury; Sildenafil Citrate; Tadalafil; Torsion Abnormality; Vardenafil Dihydrochloride | 2019 |
Sildenafil and tadalafil reduce the risk of contrast-induced nephropathy by modulating the oxidant/antioxidant balance in a murine model.
Topics: Acetylcysteine; Animals; Antioxidants; Catalase; Contrast Media; Disease Models, Animal; Glutathione; Kidney Diseases; Male; Mice; Oxidants; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil; Thiobarbituric Acid Reactive Substances | 2020 |
To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Bayes Theorem; Drug Therapy, Combination; Humans; Male; Meta-Analysis as Topic; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Research Design; Sildenafil Citrate; Systematic Review as Topic; Tadalafil; Tamsulosin; Vardenafil Dihydrochloride | 2020 |
Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Topics: Adult; Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Medicare; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Prescriptions; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; Vardenafil Dihydrochloride | 2020 |
Fibromuscular dysplasia and coronary artery fistula: links to pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Coronary Artery Disease; Female; Fibromuscular Dysplasia; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Tadalafil; Vascular Fistula; Vasodilator Agents | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Simultaneous analysis of 31 anti-impotence compounds potentially illegally added to herbal-based dietary supplements by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Dietary Supplements; Drug Contamination; Drugs, Chinese Herbal; Erectile Dysfunction; Food Safety; Humans; Limit of Detection; Male; Molecular Structure; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry | 2020 |
Identification of Erectile Dysfunction Drugs in Dietary Supplements by Liquid Chromatography Ion Trap Mass Spectrometry.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Dietary Supplements; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2021 |
Reliable screening and classification of phosphodiesterase type 5 inhibitors in dietary supplements using gas chromatography / mass spectrometry combined with specific common ions.
Topics: Dietary Supplements; Discriminant Analysis; Drug Evaluation, Preclinical; Gas Chromatography-Mass Spectrometry; Ions; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Time Factors; Vardenafil Dihydrochloride | 2020 |
Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography-Hybrid Ion Trap-Time of Flight Mass Spectrometry.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Cyclic Nucleotide Phosphodiesterases, Type 5; Dietary Supplements; Drug Contamination; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2020 |
The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Incidence; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Proportional Hazards Models; Retrospective Studies; Sildenafil Citrate; Tadalafil; United States; United States Department of Veterans Affairs; Veterans Health Services | 2020 |
Phosphodiesterase-5 inhibitors ameliorate structural kidney damage in a rat model of contrast-induced nephropathy.
Topics: Animals; Contrast Media; Kidney Diseases; Kidney Tubules; Male; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil | 2020 |
The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
Topics: Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Estrogens; Humans; Hypertension; Inflammation; Interleukins; Models, Animal; Models, Biological; Nitric Oxide; Obesity; Off-Label Use; Pandemics; Peptidyl-Dipeptidase A; Phosphodiesterase 5 Inhibitors; Pneumonia, Viral; Receptors, Virus; SARS-CoV-2; Sildenafil Citrate; Tadalafil | 2020 |
UHPLC for quality evaluation of genuine and illegal medicines containing sildenafil citrate and tadalafil.
Topics: Chromatography, High Pressure Liquid; Counterfeit Drugs; Illicit Drugs; Limit of Detection; Linear Models; Reproducibility of Results; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry | 2021 |
Erectile dysfunction drugs altered the activities of antioxidant enzymes, oxidative stress and the protein expressions of some cytochrome P450 isozymes involved in the steroidogenesis of steroid hormones.
Topics: Animals; Antioxidants; Cytochrome P-450 Enzyme System; Erectile Dysfunction; Glutathione; Isoenzymes; Liver; Male; Oxidative Stress; Rabbits; Sildenafil Citrate; Steroids; Tadalafil; Testis; Thiobarbituric Acid Reactive Substances; Vardenafil Dihydrochloride | 2020 |
Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma.
Topics: Aflatoxin B1; Animals; Antioxidants; Carcinoma, Hepatocellular; Lipid Peroxidation; Liver Neoplasms, Experimental; Male; Phosphodiesterase 5 Inhibitors; Poisons; Rats; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2021 |
Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Contraindications, Drug; Death, Sudden, Cardiac; Erectile Dysfunction; Forensic Medicine; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Risk; Sexual Behavior; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2021 |
[PDE-5i combined with RigiScan-based audiovisual sexual stimulation test versus nocturnal penile tumescence test in evaluation of erectile function].
Topics: Adult; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Young Adult | 2020 |
Lactic acid inhibits iNKT cell functions via a phosphodiesterase-5 dependent pathway.
Topics: Animals; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytokines; Interferon-gamma; Lactic Acid; Mice; Mice, Inbred C57BL; Natural Killer T-Cells; Neoplasms; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2021 |
Effects of sildenafil and tadalafil on skin flap viability.
Topics: Administration, Oral; Animals; Male; Models, Animal; Rats; Rats, Wistar; Sildenafil Citrate; Skin Neoplasms; Skin Transplantation; Surgical Flaps; Tadalafil; Vasodilator Agents; Wound Healing | 2022 |
Detection of 94 compounds related to sexual enhancement including sildenafil, tadalafil, vardenafil and their analogues in various formulations of dietary supplements and food samples using HPLC and LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Dietary Supplements; Drug Contamination; Food Analysis; Food Contamination; Humans; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2021 |
Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An
Topics: Acrosome Reaction; Adult; Cell Culture Techniques; Humans; Male; Phosphodiesterase 5 Inhibitors; Semen Analysis; Sildenafil Citrate; Sperm Count; Sperm Motility; Tadalafil | 2021 |
Detection Method of Falsified Medicines by Using a Low-Cost Raman Scattering Spectrometer Combined with Soft Independent Modeling of Class Analogy and Partial Least Squares Discriminant Analysis.
Topics: Counterfeit Drugs; Fluconazole; Least-Squares Analysis; Models, Chemical; Sildenafil Citrate; Spectrum Analysis, Raman; Tablets; Tadalafil; Vardenafil Dihydrochloride | 2021 |
[Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2021 |
Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Patient Preference; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil | 2022 |
Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i.
Topics: Adolescent; Adult; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Treatment Outcome; Young Adult | 2021 |
Identifying the most relevant tablet regions in the image detection of counterfeit medicines.
Topics: Counterfeit Drugs; Sildenafil Citrate; Tablets; Tadalafil | 2021 |
Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
Topics: Animals; Cell Line, Tumor; HEK293 Cells; Humans; Male; Mice; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Protein Isoforms; Purines; Second Messenger Systems; Sildenafil Citrate; Steroids; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2022 |
Contemporary cost-analysis comparison of direct-to-consumer vs. traditional prescriptions of phosphodiesterase-5 inhibitors.
Topics: Aged; Canada; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; National Health Programs; Phosphodiesterase 5 Inhibitors; Prescriptions; Sildenafil Citrate; Tadalafil; United States | 2023 |
Detection of 94 PDE-5is and Their Analogs Including N-Desmethylthiosildenafil in Various Formulations of Dietary Supplements and Food Samples Using HPLC and LC-Q-TOF/MS.
Topics: Chromatography, High Pressure Liquid; Dietary Supplements; Drug Contamination; Humans; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2022 |
Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
Topics: Aflatoxin B1; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbolines; Carcinoma, Hepatocellular; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Repositioning; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glucose; Imidazoles; Liver Neoplasms; Neoplasm Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2022 |
Screening and Determination of Synthetic PDE-5 Inhibitors in Adulterated Sexual Enhancement Supplements.
Topics: Dietary Supplements; Drug Contamination; Humans; Pharmaceutical Preparations; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry; Vardenafil Dihydrochloride | 2022 |
UV-responsive fluorescent behavior of pharmaceuticals assessed by UV-induced fingerprint spectroscopy (UV-IFS).
Topics: Acetaminophen; Loratadine; Sildenafil Citrate; Spectrum Analysis; Tablets; Tadalafil | 2022 |
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.
Topics: Carbolines; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Purines; Sildenafil Citrate; Tadalafil | 2023 |
Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Topics: Adolescent; Adult; Erectile Dysfunction; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Pharmacovigilance; Phosphodiesterase 5 Inhibitors; Priapism; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; World Health Organization | 2023 |
Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Topics: Child; Cost-Benefit Analysis; Humans; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Sildenafil Citrate; Tadalafil | 2023 |
Re: Moritz von Büren, Severin Rodler, Isabell Wiesenhütter, et al. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. Eur Urol Focus 2022;8:794-802.
Topics: Erectile Dysfunction; Humans; Male; Patient Preference; Sildenafil Citrate; Tadalafil | 2023 |
Reply to Eugenio Ventimiglia, Andrea Salonia, and Francesco Montorsi's Letter to the Editor re: Moritz von Büren, Severin Rodler, Isabell Wiesenhütter, et al. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients wit
Topics: Erectile Dysfunction; Humans; Male; Patient Preference; Sildenafil Citrate; Tadalafil | 2023 |
Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements.
Topics: Chromatography, High Pressure Liquid; Cyclic Nucleotide Phosphodiesterases, Type 5; Dietary Supplements; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2023 |
Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry.
Topics: Carbolines; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vardenafil Dihydrochloride | 2024 |
A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals.
Topics: Humans; Male; Penile Induration; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tamoxifen; Triazines; Vardenafil Dihydrochloride | 2023 |
A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer's disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2023 |
Phosphodiesterase-5 inhibitors tadalafil and sildenafil potentiate nitrergic-nerve mediated relaxations in the bladder vasculature.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Nitric Oxide; Norepinephrine; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Swine; Tadalafil; Urinary Bladder; Vasodilation | 2023 |
Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility.
Topics: Animals; Anticonvulsants; Diazepam; Humans; Male; Pentylenetetrazole; Phenobarbital; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Seizures; Sildenafil Citrate; Sulfones; Tadalafil | 2023 |